aminolevulinic acid and Skin Neoplasms studies

Aminolevulinic Acid: A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS.
5-aminolevulinic acid : The simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp.

Research Excerpts

Excerpt	Relevance	Reference
"Photodynamic therapy using topical methyl 5-aminolevulinate (MAL) is a new treatment modality for basal cell carcinoma (BCC) and actinic keratosis (AK)."	9.12	Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. ( Angell-Petersen, E; Giercksky, KE; Moan, J; Peng, Q; Soler, AM; Sørensen, R; Warloe, T, 2006)
"The present research work describes the use of photodynamic therapy (PDT) of drug 5-aminolevulinic acid (5-ALA) conjugated with microbial synthesised silver nanoparticles on skin melanoma (B16F10) and epidermoid carcinoma (A431) cell lines."	7.91	Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles. ( Sanjay, KR; Shivashankarappa, A, 2019)
"5-aminolevulinic acid heptyl ester was investigated in human adenocarcinoma WiDr cells and in healthy skin of athymic nude mice in comparison with 5-aminolevulinic acid (ALA)."	7.75	A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin. ( Iani, V; Juzeniene, A; Ma, LW; Moan, J; Pudroma, X, 2009)
" In this study, we used 5-aminolevulinic (ALA) acid and 3 water soluble photosensitizers-PP(Arg)(2), PP(Ser)(2)Arg(2), PP(Ala)(2)Arg(2), all diamino acid derivatives of protoporphyrin IX-to treat benign papillomas in FVB/N mice induced by 7,12-dimethylbenz(a)anthracene (DMBA)-12-O-tetradecanoyl-phorbol-13-acetate (TPA)."	7.75	Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin. ( Dziadziuszko, H; Glosnicka, R; Graczyk, A; Jankowski, D; Jaskiewicz, K; Juzeniene, A; Kaliszewski, M; Kunikowska, D; Kwasny, M; Kwitniewski, M; Ma, LW; Moan, J; Peksa, R, 2009)
"In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain."	7.74	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"Photodynamic therapy with topical delta-aminolevulinic acid using approximately 40 mW/cm(2) at 633 nm is photodynamically efficient with minimum pain."	7.74	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"We report the case of a 82-year-old man who, after multiple treatments with aminolevulinic acid photodynamic therapy for solar keratoses and superficial squamous cell carcinomas, developed malignant melanoma at the exposed site on the scalp."	7.69	Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. ( Fink-Puches, R; Kerl, H; Reimann-Weber, A; Wolf, P, 1997)
" Mild or moderate adverse effects were similar for both groups."	6.87	Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial. ( Abbade, LPF; Ferreira, ER; Lima, TRR; Miola, AC; Miot, HA; Schmitt, JV, 2018)
"COL 0·5% cream and MAL-PDT are safe and effective for treating SFC."	6.87	Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial. ( Abbade, LPF; Ferreira, ER; Lima, TRR; Miola, AC; Miot, HA; Schmitt, JV, 2018)
"Pain was assessed pre-illumination, during, and immediately after illumination, using a numeric rating scale."	6.72	Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. ( Haedersdal, M; Philipsen, PA; Skiveren, J; Wiegell, SR; Wulf, HC, 2006)
"A total of six cases of ulcerative squamous cell carcinoma were included in our study."	5.56	Efficacy and safety of 5-aminolevulinic acid photodynamic therapy for the treatment of ulcerative squamous cell carcinoma. ( Dong, L; Li, X; Lu, Y; Shen, X; Wang, Y; Zhang, J; Zhang, W, 2020)
"Silver nanoparticles were synthesised using the bacterial strain Bacillus licheniformis."	5.51	Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles. ( Sanjay, KR; Shivashankarappa, A, 2019)
" Herpes zoster is a common and painful disease caused by the reactivation of the varicella-zoster virus with a higher incidence and severity associated with increasing age as well as compromised immune status."	5.46	Temporal Association of Herpes Zoster Eruption Post-Aminolevulinic Acid Hydrochloride Photodynamic Therapy for Actinic Keratoses. ( Cohen, JL; Manno, K, 2017)
"Pain was monitored."	5.35	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"When PpIX was 90% bleached, irradiance was increased to 150 mW/cm(2) until 200 J/cm(2) were delivered."	5.35	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"Once PpIX is largely photobleached, higher irradiances allow efficient, rapid delivery of additional light."	5.35	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"5-aminolevulinic acid heptyl ester was investigated in human adenocarcinoma WiDr cells and in healthy skin of athymic nude mice in comparison with 5-aminolevulinic acid (ALA)."	5.35	A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin. ( Iani, V; Juzeniene, A; Ma, LW; Moan, J; Pudroma, X, 2009)
"Photodynamic therapy using topical methyl 5-aminolevulinate (MAL) is a new treatment modality for basal cell carcinoma (BCC) and actinic keratosis (AK)."	5.12	Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. ( Angell-Petersen, E; Giercksky, KE; Moan, J; Peng, Q; Soler, AM; Sørensen, R; Warloe, T, 2006)
"Photodynamic therapy (PDT) using topical delta-aminolevulinic acid (delta-ALA) is an effective treatment for Bowen disease and certain basal cell carcinomas (BCCs), but its place in clinical practice remains to be established."	5.09	Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. ( MacKie, RM; McColl, JH; Moore, JV; Morton, CA; Whitehurst, C, 2001)
"Methyl aminolevulinate (MAL), an ester of aminolevulinic acid, has been used effectively as a topical photosensitizing agent in the photodynamic therapy (PDT) of epidermal lesions such as actinic keratosis (AK) and basal cell carcinoma (BCC)."	4.82	Topical methyl aminolevulinate. ( Perry, CM; Scott, LJ; Siddiqui, MA, 2004)
"We have reviewed the results of clinical investigations into the use of photodynamic therapy (PDT) with intravenous injection of hematoporphyrin derivative (HpD), Photofrin (PF) and Sn-protoporphyrin (Sn-Pp) or oral administration of delta-aminolevulinic acid in the treatment of skin cancers and/or psoriasis."	4.79	Photodynamic therapy with systemic administration of photosensitizers in dermatology. ( Calzavara-Pinton, PG; Ortel, B; Szeimies, RM; Zane, C, 1996)
"Studies comparing 5-fluorouracil (5-FU), imiquimod, and photodynamic therapy with aminolevulinic acid (PDT-ALA) have evaluated the efficacy of destroying actinic keratosis (AK)."	4.12	A comparison of invasive squamous cell carcinoma greater than 1 year after treatment with 5-fluorouracil, imiquimod, or photodynamic therapy with aminolevulinic acid. ( Cheng, B; Etzkorn, JR; Giordano, CN; Higgins, HW; Miller, CJ; Shin, TM; Sobanko, JF; Veerabagu, S, 2022)
"Photodynamic therapy (PDT) has been reported as a treatment for cutaneous squamous cell carcinoma in situ (SCCis), but only limited data are available on the effectiveness of PDT with aminolevulinic acid (ALA-PDT)."	3.96	Photodynamic therapy for cutaneous squamous cell carcinoma in situ: Impact of anatomic location, tumor diameter, and incubation time on effectiveness. ( Christensen, SR; Kibbi, N; Leffell, DJ; Zhang, Y, 2020)
"The present research work describes the use of photodynamic therapy (PDT) of drug 5-aminolevulinic acid (5-ALA) conjugated with microbial synthesised silver nanoparticles on skin melanoma (B16F10) and epidermoid carcinoma (A431) cell lines."	3.91	Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles. ( Sanjay, KR; Shivashankarappa, A, 2019)
"Photodynamic therapy (PDT) with topical δ-aminolevulinic acid (ALA) of non-melanoma skin cancers is often associated with treatment-limiting pain."	3.79	A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013)
" In the present study, the efficacy of topical hypericin-PDT was evaluated using a mouse model for actinic keratosis."	3.77	Photodynamic therapy using topically applied hypericin: comparative effect with methyl-aminolevulinic acid on UV induced skin tumours. ( Boiy, A; de Witte, PA; Roelandts, R, 2011)
"5-aminolevulinic acid heptyl ester was investigated in human adenocarcinoma WiDr cells and in healthy skin of athymic nude mice in comparison with 5-aminolevulinic acid (ALA)."	3.75	A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin. ( Iani, V; Juzeniene, A; Ma, LW; Moan, J; Pudroma, X, 2009)
" In this study, we used 5-aminolevulinic (ALA) acid and 3 water soluble photosensitizers-PP(Arg)(2), PP(Ser)(2)Arg(2), PP(Ala)(2)Arg(2), all diamino acid derivatives of protoporphyrin IX-to treat benign papillomas in FVB/N mice induced by 7,12-dimethylbenz(a)anthracene (DMBA)-12-O-tetradecanoyl-phorbol-13-acetate (TPA)."	3.75	Photodynamic therapy with 5-aminolevulinic acid and diamino acid derivatives of protoporphyrin IX reduces papillomas in mice without eliminating transformation into squamous cell carcinoma of the skin. ( Dziadziuszko, H; Glosnicka, R; Graczyk, A; Jankowski, D; Jaskiewicz, K; Juzeniene, A; Kaliszewski, M; Kunikowska, D; Kwasny, M; Kwitniewski, M; Ma, LW; Moan, J; Peksa, R, 2009)
"In superficial basal cell carcinomas treated with photodynamic therapy with topical delta-aminolevulinic acid, we examined effects of light irradiance on photodynamic efficiency and pain."	3.74	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"Photodynamic therapy with topical delta-aminolevulinic acid using approximately 40 mW/cm(2) at 633 nm is photodynamically efficient with minimum pain."	3.74	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"We present the kinetics of ALA-induced protoporphyrin IX (PP) accumulation and the results of ALA PDT treatment on two patients with different stages (stage I and stage III) of mycosis fungoides (MF)-type cutaneous T-cell lymphoma (CTCL)."	3.70	Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application. ( Haik, J; Kostenich, G; Malik, Z; Orenstein, A; Tamir, J; Trau, H; Winkler, E, 2000)
"We report a case of psoriasis reactivation following photodynamic therapy with delta-aminolevulinic acid."	3.69	Købner reaction induced by photodynamic therapy using delta-aminolevulinic acid. A case report. ( Stender, IM; Wulf, HC, 1996)
"We report the case of a 82-year-old man who, after multiple treatments with aminolevulinic acid photodynamic therapy for solar keratoses and superficial squamous cell carcinomas, developed malignant melanoma at the exposed site on the scalp."	3.69	Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. ( Fink-Puches, R; Kerl, H; Reimann-Weber, A; Wolf, P, 1997)
"Photodynamic therapy (PDT) with topical application of delta-aminolevulinic acid (ALA) followed by irradiation with visible light (ALA-PDT) is a relatively new and promising experimental treatment of superficial premalignant and malignant skin neoplasms."	3.69	Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. ( Bech-Thomsen, N; Poulsen, T; Stender, IM; Wulf, HC, 1997)
"Week 52 lesion recurrence rates were 7."	2.94	A Randomized Trial of Broad Area ALA-PDT for Field Cancerization Mitigation in High-Risk Patients. ( Berg, JE; Ferdon, MB; Houlihan, A; Marcus, SL; Piacquadio, D, 2020)
" Mild or moderate adverse effects were similar for both groups."	2.87	Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial. ( Abbade, LPF; Ferreira, ER; Lima, TRR; Miola, AC; Miot, HA; Schmitt, JV, 2018)
"COL 0·5% cream and MAL-PDT are safe and effective for treating SFC."	2.87	Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial. ( Abbade, LPF; Ferreira, ER; Lima, TRR; Miola, AC; Miot, HA; Schmitt, JV, 2018)
"BACKGROUND Squamous cell carcinoma (SCC) is the second most common type of skin cancer, for which non- or mini-invasive treatment is of critical importance."	2.84	A Clinical Trial Using Attrition Combined with 5-Aminolevulinic Acids Based Photodynamic Therapy in Treating Squamous Cell Carcinoma. ( Dai, Y; Feng, W; Luo, X; Peng, J; Wang, T; Xiang, W; Zheng, J; Zhu, J, 2017)
"Skin cancer is considered a risky worldwide disease."	2.82	The combinational application of photodynamic therapy and nanotechnology in skin cancer treatment: A review. ( Adnane, F; El-Zayat, E; Fahmy, HM, 2022)
" All patients were able to complete the treatment protocol, with well cosmetic results and no moderate adverse reactions."	2.80	Efficacy and safety of topical ALA-PDT in the treatment of EMPD. ( Fan, DL; Gao, Y; Lu, YG; Wang, HL; Wang, WS; Yang, Y; Zhang, XC, 2015)
" In this study, we evaluated the feasibility and efficacy of aminolevulinic acid (ALA) as a photosensitizer (ALA-PDT) in combination with CO2 laser in the treatment of Bowen's disease (BD; intraepithelial squamous cell carcinoma)."	2.80	Photodynamic therapy in combination with CO2 laser for the treatment of Bowen's disease. ( Cai, H; Li, Q; Li, YL; Liu, W; Liu, XY; Sun, P; Wang, YX; Yang, ZY; Zheng, JC, 2015)
" Over the following 2 years, some investigators noted and formally reported the continued occurrence of serious adverse events in excess of those described with other approved cutaneous PDT treatments."	2.79	Prolonged adverse events following photodynamic therapy: regulatory implications. ( Anderson, SJ; Dixon, AJ; Mazzurco, JD; Steinman, HK, 2014)
" It is of concern that this ALA product and lamp could be promoted and used widely in Australia following these reports of significant adverse events and continued lack of TGA approval."	2.79	Prolonged adverse events following photodynamic therapy: regulatory implications. ( Anderson, SJ; Dixon, AJ; Mazzurco, JD; Steinman, HK, 2014)
"Development of new skin cancers."	2.79	Prolonged adverse events following photodynamic therapy: regulatory implications. ( Anderson, SJ; Dixon, AJ; Mazzurco, JD; Steinman, HK, 2014)
"A protocol was defined for the treatment of basal cell carcinoma with 20% MAL cream application."	2.79	Experience and BCC subtypes as determinants of MAL-PDT response: preliminary results of a national Brazilian project. ( Bagnato, VS; Buzzá, HH; de Andrade, CT; Greco, C; Inada, NM; Kurachi, C; Moriyama, LT; Pires, L; Ramirez, DP; Salvio, AG; Vollet Filho, JD, 2014)
"Non-melanoma skin cancer is the most prevalent cancer type in Brazil and worldwide."	2.79	Experience and BCC subtypes as determinants of MAL-PDT response: preliminary results of a national Brazilian project. ( Bagnato, VS; Buzzá, HH; de Andrade, CT; Greco, C; Inada, NM; Kurachi, C; Moriyama, LT; Pires, L; Ramirez, DP; Salvio, AG; Vollet Filho, JD, 2014)
" The purpose of this study was to evaluate the efficacy of topical PDT using aminolevulinic acid (5-ALA) combined with excision in the treatment of skin malignant tumor and its role in surgical improvements."	2.79	Efficacy of topical ALA-PDT combined with excision in the treatment of skin malignant tumor. ( Gao, Y; Li, GL; Lu, YG; Wang, YY; Yang, Y; Yang, YD; Zhang, JB; Zhang, XC, 2014)
"Plaque-phase mycosis fungoides is among the most promising possibilities for the use of this treatment."	2.75	[Plaque-phase mycosis fungoides treated with photodynamic therapy: results from 12 patients]. ( De Las Heras, E; Fernández-Guarino, M; Harto, A; Jaén, P; Montull, C; Pérez-García, B, 2010)
"Treatment of non-melanoma skin cancers (NMSC) with topical photodynamic therapy (PDT) is a treatment of choice for many clinicians."	2.74	A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin. ( Ferguson, J; Lesar, A; Moseley, H, 2009)
"Residual tumor was found in 15 (75%) AK and in 4 (66."	2.73	Fractionated illumination improves the outcome in the treatment of precancerous lesions with photodynamic therapy. ( Mirić, L; Persin, A; Puizina-Ivić, N; Vanjaka-Rogosić, L; Zorc, H, 2008)
" This method of enhancement was safely applied to a clinical PDT protocol with no unexpected adverse effects reported."	2.73	Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. ( Campbell, S; Curnow, A; Pye, A, 2008)
"This limits the treatment of basal cell carcinoma (non-melanoma skin cancer) to superficial forms and nodular therapy (only in aesthetically desired locations)."	2.73	Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. ( Smucler, R; Vlk, M, 2008)
"Fluorouracil was applied for 4 weeks."	2.72	Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. ( Bedane, C; Horn, M; Ibbotson, S; Khemis, A; Leman, J; Morton, C; Tack, B; Tjioe, M; Wolf, P, 2006)
"Pain was assessed pre-illumination, during, and immediately after illumination, using a numeric rating scale."	2.72	Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. ( Haedersdal, M; Philipsen, PA; Skiveren, J; Wiegell, SR; Wulf, HC, 2006)
"Conventional treatment of basal cell carcinoma (BCC) causes morbidity and/or disfigurement in some patients because of the location (e."	2.71	Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. ( De Rie, M; Fritsch, C; Horn, M; Kaufmann, R; Larkö, O; Legat, FJ; Rhodes, LE; Solér, AM; Stender, IM; Warloe, T; Wennberg, AM; Wolf, P; Wong, GA; Wulf, HC, 2003)
"After a single treatment, 47 (85%) basal cell carcinomas showed a complete response at a follow-up time of at least 6 months."	2.69	Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. ( Hänggi, G; Hürlimann, AF; Panizzon, RG, 1998)
"There was a patient with Bowen's disease of the penis."	2.69	[Topical photodynamic therapy in basal and squamous cell carcinoma and penile Bowen's disease with 20% aminolevulinic acid, and exposure to red light and infrared light]. ( Harth, Y; Hirshovitz, B, 1998)
"For large areas of Bowen's disease, particularly in anatomically difficult areas and in elderly patients, PDT using ALA may constitute a single simple alternative outpatient treatment to existing therapies."	2.67	Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. ( Ash, DV; Brown, SB; Cairnduff, F; Hudson, EJ; Stringer, MR, 1994)
"A better understanding of why cancer cells fluoresce with 5-ALA would improve its use in cancer diagnostics and therapies."	2.61	In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid? ( Gleadle, JM; MacGregor, MN; McNicholas, K, 2019)
"Selection of appropriate treatment for mycosis fungoides (MF) is based on prognostic factors and overall clinical stage at diagnosis."	2.58	Photodynamic therapy as an alternative treatment for mycosis fungoides: a systemic review and meta-analysis. ( Cazzaniga, S; Hunger, RE; Seyed Jafari, SM, 2018)
"Mycosis fungoides is the most common cutaneous T cell lymphoma."	2.58	Photodynamic therapy as an alternative treatment for mycosis fungoides: a systemic review and meta-analysis. ( Cazzaniga, S; Hunger, RE; Seyed Jafari, SM, 2018)
"Mycosis fungoides is the most common cutaneous T-cell lymphoma."	2.55	Photodynamic therapy as an alternative treatment for relapsed or refractory mycosis fungoides: A systemic review. ( Liu, C; Liu, Y; Xue, J, 2017)
"Surgical excision (SE) is a first-line treatment for basal cell carcinoma (BCC)."	2.53	Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. ( Han, J; Li, J; Lin, H; Luo, X; Ye, Z; Yu, J; Zhao, Y; Zou, Y, 2016)
"In general, people with Bowen's disease have an excellent prognosis because the disease is typically slow-growing and responds favourably to treatment."	2.49	Interventions for cutaneous Bowen's disease. ( Bath-Hextall, FJ; Leonardi-Bee, J; Matin, RN; Wilkinson, D, 2013)
"Bowen's disease is the clinical term for in situ squamous cell carcinoma of the skin."	2.49	Interventions for cutaneous Bowen's disease. ( Bath-Hextall, FJ; Leonardi-Bee, J; Matin, RN; Wilkinson, D, 2013)
"With regard to squamous cell carcinoma, treatment with 5-fluorouracil, methotrexate, interferon, and bleomycin are reviewed."	2.47	Intralesional agents in the management of cutaneous malignancy: a review. ( Good, LM; High, WA; Miller, MD, 2011)
"However, PDT pain is multifactorial and choice of photosensitiser is probably not a major pain determining factor."	2.47	A review of pain experienced during topical photodynamic therapy--our experience in Dundee. ( Attili, SK; Dawe, R; Ibbotson, S, 2011)
"As the incidence of skin cancer is rising, an optimized treatment in non-melanoma skin cancer is needed."	2.45	Optimizing ALA-PDT in the management of non-melanoma skin cancer by fractionated illumination. ( De Bruijn, HS; De Haas, ER; De Vijlder, HC; Martino Neumann, HA; Middelburg, T; Robinson, DJ; Sterenborg, HC, 2009)
"The response rate of Bowen's disease to MAL-PDT is also at least equivalent to cryotherapy and 5-fluorouracil, again with superior cosmesis."	2.44	Methyl aminolevulinate: actinic keratoses and Bowen's disease. ( Morton, CA, 2007)
"Aminolevulinic acid (ALA) has been shown to be the drug with most experimental and clinical use in the past."	2.43	Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods. ( Fritsch, C; Ruzicka, T, 2006)
"Actinic keratosis is currently believed to be an early stage in the evolution of squamous cell carcinoma."	2.42	Topical and light-based treatments for actinic keratoses. ( Alam, M; Goldberg, LH; Silapunt, S, 2003)
"As the first stage of squamous cell carcinoma, actinic keratosis is worthy of prompt evaluation and active treatment."	2.42	Topical and light-based treatments for actinic keratoses. ( Alam, M; Goldberg, LH; Silapunt, S, 2003)
"No new basal cell carcinomas were observed during the 8-month follow-up period in areas treated with a broad application technique."	2.42	delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. ( Gilchrest, BA; Itkin, A, 2004)
"Patients with nevoid basal cell carcinoma syndrome suffer from multiple basal cell carcinomas, requiring numerous surgical procedures that over time leave them with multiple disfiguring scars."	2.42	delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. ( Gilchrest, BA; Itkin, A, 2004)
"We report treatment of two nevoid basal cell carcinoma syndrome patients, women aged 21 and 47, with 20%delta-aminolevulinic acid solution and 417-nm blue light source (irradiance 10 mW/cm(2))."	2.42	delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. ( Gilchrest, BA; Itkin, A, 2004)
"The incidence of basal cell carcinoma is increasing."	2.41	Basal cell carcinoma--new aspects of diagnosis and treatment. ( Wennberg, AM, 2000)
"Photodynamic therapy (PDT) for cancer patients has developed into an important new clinical treatment modality in the past 25-years."	2.40	5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. ( Berg, K; Giercksky, KE; Kongshaug, M; Moan, J; Nesland, JM; Peng, Q; Warloe, T, 1997)
"5-aminolevulinic acid is an early intermediate product in the synthesis of heme."	2.40	[Use of 5-aminolevulinic acid in photochemotherapy and fluorescence diagnostics]. ( Bech, O; Berg, K; Moan, J; Peng, Q, 1998)
"Its use in the treatment of psoriasis has been attempted only quite recently and some modest success achieved."	2.39	Photodynamic therapy for psoriasis? ( Fergin, P, 1996)
"Bowen's disease was highly responsive, provided that adequate light and HpD or PF doses were delivered."	2.39	Photodynamic therapy with systemic administration of photosensitizers in dermatology. ( Calzavara-Pinton, PG; Ortel, B; Szeimies, RM; Zane, C, 1996)
"Nanogels co-cultured with skin cancer cells (A2058) allowed the efficiency of the PDT in vitro to be demonstrated."	1.91	Development of biodegradable nanogels for lipase accelerated drug release of 5-aminolevulinic acid. ( Bradley, M; Ge, K; Liu, X; Sheng, Y; Sun, Y; Zhang, P; Zhang, R; Zhang, Y, 2023)
"We present one case of vulvar extramammary Paget's disease (EMPD), that is a female patient with lesions in the vulva and involving the urethra."	1.91	Efficacy of hematoporphyrin injection (HpD) photodynamic therapy in the treatment of widespread extramammary Paget's disease. ( Li, Y; Liu, R; Liu, X; Ma, G; Ma, T; Tang, Y; Xiang, X, 2023)
"The ALA-PDL-PDT protocol is a safe and well-tolerated treatment option for isSCC on the face, providing excellent cosmetic and functional results."	1.91	Evaluating the safety and efficacy of aminolevulinic acid 20% topical solution activated by pulsed dye laser and blue light in the treatment of facial cutaneous squamous cell carcinoma in situ. ( Ceci, FM; Gade, A; Han, H; Lawson, A; Nestor, MS, 2023)
"Non-melanoma skin cancer (NMSC) is the most common malignancy worldwide, with rising incidence in the recent years."	1.72	In vitro 5-Fluorouracil resistance produces enhanced photodynamic therapy damage in SCC and tumor resistance in BCC. ( Gilaberte, Y; González, S; Gutiérrez-Pérez, M; Juarranz, Á; Nicolás-Morala, J; Portillo-Esnaola, M; Terrén, S, 2022)
"Multiple large lesions of Bowen's disease (BD) often appear in patients who have been under chronic exposure to arsenic."	1.72	Successful treatment of giant Bowen's disease with photodynamic therapy and subsequent imiquimod in a case with chronic arsenic exposure. ( Chen, YC; Liu, WT; Lo, TK; Wong, TW, 2022)
"Non-melanoma skin cancer patients have received six cycles of 0."	1.72	A retrospective study comparing different injection approaches of 5-aminolevulinic acid in patients with non-melanoma skin cancer. ( Wang, J; Zhang, Y; Zhao, W; Zheng, B, 2022)
" To explore the efficacy and safety of dermabrasion combined with PDT (D-PDT) for the treatment of NMSCs."	1.72	Dermabrasion combined with photodynamic therapy: a new option for the treatment of non-melanoma skin cancer. ( Bu, W; Chen, M; Chen, X; Fang, F; He, R; Huang, K; Li, F; Luo, X; Su, J; Wei, T; Wu, L; Xie, Y; Yu, J; Yu, N; Zhang, L; Zhang, Q; Zhao, S, 2022)
"Non-melanoma skin cancer (NMSC) is the most common malignancy."	1.72	Dermabrasion combined with photodynamic therapy: a new option for the treatment of non-melanoma skin cancer. ( Bu, W; Chen, M; Chen, X; Fang, F; He, R; Huang, K; Li, F; Luo, X; Su, J; Wei, T; Wu, L; Xie, Y; Yu, J; Yu, N; Zhang, L; Zhang, Q; Zhao, S, 2022)
"As for side effects, hypertrophic scar and pain were observed."	1.62	Bimodal photodynamic therapy for treatment of a 91-year-old patient with locally advanced cutaneous basal cell carcinoma and postoperative scar management. ( Liao, C; Shi, L; Wang, D; Wang, X, 2021)
"Basal cell carcinoma is the most common cancer."	1.62	Treatment of cutaneous basal cell carcinoma with combined laser extirpation and methyl aminolevulinic acid: five-year success rates. ( Abdelrahman, W; Azzopardi, E; Azzopardi, EA; Barbara, C; Camilleri, L; Clementoni, MT; Miles, N; Murison, M; O'Leary, B; Yarrow, J, 2021)
"Nodular basal cell carcinoma was the most common subtype (41."	1.62	Treatment of cutaneous basal cell carcinoma with combined laser extirpation and methyl aminolevulinic acid: five-year success rates. ( Abdelrahman, W; Azzopardi, E; Azzopardi, EA; Barbara, C; Camilleri, L; Clementoni, MT; Miles, N; Murison, M; O'Leary, B; Yarrow, J, 2021)
"Protoporphyrin IX (PpIX) is an endogenous photosensitizer (PS) widely used, obtained by the administration of precursors such as aminolevulinic acid and methyl aminolevulinate."	1.56	Use of dermograph for improvement of PpIX precursor's delivery in photodynamic therapy: Experimental and clinical pilot studies. ( Bagnato, VS; Fortunato, TC; Pratavieira, S; Requena, MB; Russignoli, PE; Salvio, AG; Vollet-Filho, JD, 2020)
"Skin squamous cell carcinoma (SCC) is the second most common skin cancer, and surgical resection is the first choice of treatment."	1.56	Photodynamic therapy for squamous cell carcinoma of the index finger: A case report. ( Ma, J; Wang, X, 2020)
"A total of six cases of ulcerative squamous cell carcinoma were included in our study."	1.56	Efficacy and safety of 5-aminolevulinic acid photodynamic therapy for the treatment of ulcerative squamous cell carcinoma. ( Dong, L; Li, X; Lu, Y; Shen, X; Wang, Y; Zhang, J; Zhang, W, 2020)
"The purpose of this study is to investigate the clinical efficacy of Mohs surgery in combination with topical photodynamic therapy (PDT) for facial basal cell carcinoma."	1.56	Clinical efficacy of Mohs surgery combined with topical photodynamic therapy for facial basal cell carcinoma. ( Kou, H; Lu, Y; Wang, Y; Yang, Y; Zhang, J; Zhang, X, 2020)
"Silver nanoparticles were synthesised using the bacterial strain Bacillus licheniformis."	1.51	Photodynamic therapy on skin melanoma and epidermoid carcinoma cells using conjugated 5-aminolevulinic acid with microbial synthesised silver nanoparticles. ( Sanjay, KR; Shivashankarappa, A, 2019)
"It is reported that ALA-PDT treating cutaneous squamous cell carcinoma(cSCC) also induce antitumor immune effect and has an impact on tumor microenvironment."	1.51	The effect of ALA-PDT on reversing the activation of cancer-associated fibroblasts in cutaneous squamous cell carcinoma. ( Ji, J; Li, S; Lv, T; Wang, H; Wang, P; Wang, X; Zhang, G, 2019)
" The purpose of this article was to study the anti-tumor effect of ALA-PDT combined with limited excision in periocular basal cell carcinoma (BCC) and its role in improving the effect of the operation."	1.51	Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma. ( Kou, H; Li, G; Li, X; Lu, Y; Tan, L; Wang, Y; Zhang, J, 2019)
"In our study, 8 patients with periocular basal cell carcinoma were treated with topical aminolevulinic acid photodynamic therapy (ALA-PDT) combined with surgery."	1.51	Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma. ( Kou, H; Li, G; Li, X; Lu, Y; Tan, L; Wang, Y; Zhang, J, 2019)
"PDT in combination with limited surgery is a safe, effective and minimally-invasive approach for treating orbital BCC."	1.51	Ocular preservation through limited tumor excision combined with ALA-PDT in patients with periocular basal cell carcinoma. ( Kou, H; Li, G; Li, X; Lu, Y; Tan, L; Wang, Y; Zhang, J, 2019)
"Initial surgical margins were determined by FD or FD plus MSB."	1.48	Clinical Benefits of Preoperative Conventional Fluorescence Diagnosis in Surgical Treatment of Extramammary Paget Disease. ( Chen, Z; Ma, H; Wan, M; Xie, L; Zhao, Y, 2018)
"Superficial basal cell carcinoma is a type of keratinocyte carcinoma that has increasing incidence and substantial morbidity."	1.48	Comparing Topical Treatments for Basal Cell Carcinoma. ( Shaw, FM; Weinstock, MA, 2018)
"We report the successful use of PDT to treat actinic keratosis and skin cancers in two patients with BP, both of whom had excellent response to PDT and tolerated treatment without any bullous disease flares."	1.46	Photodynamic therapy effective for the treatment of actinic keratosis and basal cell carcinoma in bullous pemphigoid patients. ( Canavan, TN; de la Feld, SF; Huang, C; Sami, N, 2017)
"Treating skin cancers and extensive actinic keratosis in patients with bullous pemphigoid (BP) can be challenging."	1.46	Photodynamic therapy effective for the treatment of actinic keratosis and basal cell carcinoma in bullous pemphigoid patients. ( Canavan, TN; de la Feld, SF; Huang, C; Sami, N, 2017)
"The treatment for giant cutaneous squamous cell carcinoma (cSCC) is challenging."	1.46	Novel strategy in giant cutaneous squamous cell carcinoma treatment: The case experience with a combination of photodynamic therapy and surgery. ( Bu, W; Chen, X; Fang, F; Wang, Y, 2017)
"Epithelioid angiosarcoma is a high grade malignancy sarcoma of soft tissue, which is hard to diagnose and completely excise without causing functional and cosmetic problems."	1.46	Treatment of Epithelioid angiosarcoma with Topical ALA-PDT in the course of surgery. ( Gao, Y; Liu, J; Lu, YG; Wang, HL; Wang, WS, 2017)
" Herpes zoster is a common and painful disease caused by the reactivation of the varicella-zoster virus with a higher incidence and severity associated with increasing age as well as compromised immune status."	1.46	Temporal Association of Herpes Zoster Eruption Post-Aminolevulinic Acid Hydrochloride Photodynamic Therapy for Actinic Keratoses. ( Cohen, JL; Manno, K, 2017)
"Non-melanoma skin cancer (NMSC) was previously reported in 51."	1.43	Actinic keratosis: a cross-sectional study of disease characteristics and treatment patterns in Danish dermatology clinics. ( Egekvist, H; Erlendsson, AM; Haedersdal, M; Lorentzen, HF; Philipsen, PA; Stausbøl-Grøn, B; Stender, IM, 2016)
"The PDT combined with a topical photosensitizer 5-aminolevulinic acid (ALA) and an intravenously injected light-sensitive agent hematoporphyrin derivative (HPD) was used to treat 26 patients with 41 skin cancer lesions in head and face."	1.43	A photodynamic therapy combined with topical 5-aminolevulinic acid and systemic hematoporphyrin derivative is more efficient but less phototoxic for cancer. ( Lin, Y; Wang, Y; Zhang, HG; Zhu, J, 2016)
"The human squamous carcinoma cell line, SCL-1, was either untreated or treated with various combinations of ALA, PDT light source and inhibitors of MAPK signaling components."	1.43	Inhibition of MAPK signaling pathways enhances cell death induced by 5-Aminolevulinic acid-photodynamic therapy in skin squamous carcinoma cells. ( Ge, X; Jiao, Y; Jing, L; Li, PA; Liu, J; Shi, Z; Wang, Y; Yu, N; Zhang, X, 2016)
" So we used surgery combined with topical photodynamic therapy (PDT) to treat SCC of the lip."	1.43	Surgery combined with topical photodynamic therapy for the treatment of squamous cell carcinoma of the lip. ( Lu, Y; Wang, Y; Yang, Y, 2016)
"Due to the unique location of the squamous cell carcinoma (SCC) of the lip, using a single method such as extended resection or radiotherapy probably causes morphological and functional defects."	1.43	Surgery combined with topical photodynamic therapy for the treatment of squamous cell carcinoma of the lip. ( Lu, Y; Wang, Y; Yang, Y, 2016)
"5-aminolevulinic acid (5-ALA) is a drug currently used for PDT and is a hydrophilic molecule at its physiological pH, and this limits its capacity to cross the stratum corneum of skin."	1.43	A Formulation Study of 5-Aminolevulinic Encapsulated in DPPC Liposomes in Melanoma Treatment. ( Chen, CL; Chou, CY; Huang, YB; Hung, SY; Lin, MW; Wu, PC, 2016)
"Referral skin cancer centre in Australia."	1.42	Post procedural pain with photodynamic therapy is more severe than skin surgery. ( Anderson, SJ; Dixon, AJ; Dixon, JB; Dixon, MP, 2015)
"5-Aminolevulinic acid (5-ALA) is a precursor of a strong photosensitizer, protoporphyrin IX (PphIX), for photodynamic therapy (PDT)."	1.42	Targeted delivery of 5-aminolevulinic acid by multifunctional hollow mesoporous silica nanoparticles for photodynamic skin cancer therapy. ( Ma, X; Qu, Q; Zhao, Y, 2015)
"Patients with Gorlin syndrome develop multiple basal cell carcinomas (BCC), for which treatment is often difficult."	1.40	Consensus recommendations for the treatment of basal cell carcinomas in Gorlin syndrome with topical methylaminolaevulinate-photodynamic therapy. ( Basset-Seguin, N; Bissonnette, R; Girard, C; Haedersdal, M; Lear, JT; Paul, C; Piaserico, S, 2014)
"Metastatic skin cancer cells SKMEL-30 were treated by 5-ALA in dark and then they were irradiated by 90-femtosecond (fs) laser with different pulse powers for different durations."	1.40	Femtosecond laser induced photodynamic therapy on 5-ALA treated SKMEL-30 cells: an efficient theranostic strategy to combat melanoma. ( Gündoğdu, Y; Kara, R; Kars, MD; Kepceoğlu, A; Kılıç, HŞ, 2014)
"Non-melanoma skin cancer is the most common cancer lesion worldwide."	1.40	Identification of skin lesions through aminolaevulinic acid-mediated photodynamic detection. ( Andrade, CT; Bagnato, VS; Kurachi, C; Salvio, AG; Vollet-Filho, JD, 2014)
"Perianal squamous cell carcinoma in situ (SCCIS) is a relatively rare intraepidermal neoplasm that has the potential to progress to invasive squamous cell carcinoma."	1.40	Combination therapy for perianal squamous cell carcinoma in situ with imiquimod and photodynamic therapy. ( Bontumasi, NM; Hurst, EA; Sheinbein, D, 2014)
"The high cure rates for Bowen's disease and the principles of photodynamic therapy, suggest that this technique may be a great option in the management of this kind of lesion."	1.39	Periungual Bowen's disease successfully treated with photodynamic therapy. ( Caldas, A; Jeunon, T; Marques-da-Costa, J; Ortiz, B; Valente, L; Zink, BS, 2013)
"Cutaneous squamous cell carcinoma (cSCC) usually has ill-defined margins because of its irregular invasive patterns."	1.39	Efficacy of photodynamic diagnosis-guided Mohs micrographic surgery in primary squamous cell carcinoma. ( Jeon, SY; Kim, KH; Song, KH, 2013)
"Pain was assessed using a visual analog scale (VAS)."	1.39	A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013)
"Pain was strongly influenced by lesion location but not by lesion type, number, or size."	1.39	A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013)
"Two of three Bowen's disease lesions showed a complete response."	1.39	A retrospective review of pain control by a two-step irradiance schedule during topical ALA-photodynamic therapy of non-melanoma skin cancer. ( Foster, TH; Henderson, BW; Housel, JP; Paquette, AD; Shi, Y; Wilding, GE; Zeitouni, NC, 2013)
"Surgical scar remodelling and clinical improvement may be accomplished via ALA/MAL-PDT, but may require repeated treatment sessions."	1.38	Surgical scar remodelling after photodynamic therapy using aminolaevulinic acid or its methylester: a retrospective, blinded study of patients with field cancerization. ( Anderson, RR; Izikson, L; Sakamoto, FH; Tannous, Z; Zurakowski, D, 2012)
"Mycosis fungoides is the most common type of cutaneous T-cell lymphoma."	1.38	Photodynamic therapy with methyl-aminolaevulinic acid for mycosis fungoides. ( Baek, JW; Jeon, YS; Kang, DY; Kang, JS; Kim, ST; Suh, KS, 2012)
"The incidence of nonmelanoma skin cancer is significantly increased in recipients of solid-organ transplants."	1.38	Photodynamic therapy for basal cell carcinomas in organ-transplant recipients. ( Guleng, GE; Helsing, P, 2012)
"Actinic keratosis is one of the most commonly treated skin conditions."	1.38	The interpretation of clinical studies on the photodynamic treatment of actinic keratosis. ( Kelleher, DK; Piazena, H, 2012)
"Calcitriol-pretreated tumors underwent enhanced apoptotic cell death after ALA-based PDT."	1.37	Vitamin D3 enhances the apoptotic response of epithelial tumors to aminolevulinate-based photodynamic therapy. ( Anand, S; Hasan, T; Maytin, EV; Wilson, C, 2011)
"Using mouse models of squamous cell skin cancer for preclinical proof of concept, we showed that calcitriol, delivered topically or intraperitoneally, increased tumoral accumulation of the PDT-activated ALA product protoporphyrin-IX (PpIX) up to 10-fold, mainly by altering expression of the porphyrin-synthesis enzymes coproporphyrinogen oxidase (increased) and ferrochelatase (decreased)."	1.37	Vitamin D3 enhances the apoptotic response of epithelial tumors to aminolevulinate-based photodynamic therapy. ( Anand, S; Hasan, T; Maytin, EV; Wilson, C, 2011)
"Clear cell Bowen's disease (BD) is a rare histopathological subtype of BD, characterized by epidermal atypical keratinocytes with clear-cell changes exceeding 80% of the tumor population."	1.36	Warty and clear-cell Bowen's disease successfully treated with photodynamic treatment. ( Sezer, E; Yuksek, J, 2010)
"In conclusion, photodynamic therapy for extramammary Paget's disease is not recommended as the first option except for scrotal cases or lesions < 4 cm in diameter."	1.36	Long-term follow-up of in situ extramammary Paget's disease in Asian skin types IV/V treated with photodynamic therapy. ( Gao, T; Hu, X; Jiao, B; Li, C; Li, Q; Liao, W; Long, HA; Lv, Y; Qi, X; Qiao, H; Wang, L; Wang, S, 2010)
"We evaluated the clinical response, recurrence and adverse events of photodynamic therapy for in situ extramammary Paget's disease in 14 male and 3 female Chinese patients with 21 lesions."	1.36	Long-term follow-up of in situ extramammary Paget's disease in Asian skin types IV/V treated with photodynamic therapy. ( Gao, T; Hu, X; Jiao, B; Li, C; Li, Q; Liao, W; Long, HA; Lv, Y; Qi, X; Qiao, H; Wang, L; Wang, S, 2010)
"Pain was monitored."	1.35	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"When PpIX was 90% bleached, irradiance was increased to 150 mW/cm(2) until 200 J/cm(2) were delivered."	1.35	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"Once PpIX is largely photobleached, higher irradiances allow efficient, rapid delivery of additional light."	1.35	Irradiance-dependent photobleaching and pain in delta-aminolevulinic acid-photodynamic therapy of superficial basal cell carcinomas. ( Cottrell, WJ; Foster, TH; Keymel, KR; Oseroff, AR; Paquette, AD, 2008)
"(R)L-sulforaphane (SF) is a compound that protects against erythema, but it can also induce DNA fragmentation that leads to cell death by apoptosis."	1.35	Effect of (R)L-sulforaphane on 5-aminolevulinic acid-mediated photodynamic therapy. ( Juzeniene, A; Mikolajewska, P; Moan, J, 2008)
"For optimal treatment of nonmelanoma skin cancer, actinic keratoses and other dermatoses improvements are required because of adverse side effects, which include pruritus, erythema, edema, and pain."	1.35	Effect of (R)L-sulforaphane on 5-aminolevulinic acid-mediated photodynamic therapy. ( Juzeniene, A; Mikolajewska, P; Moan, J, 2008)
" However, in the case of deep, nodular-ulcerative lesions, the complete response rates are lower, possibly related to a lower bioavailability of PpIX."	1.35	Comparison of ALA- and ALA hexyl-ester-induced PpIX depth distribution in human skin carcinoma. ( Ballini, JP; Dögnitz, N; Gabrecht, T; Lange, N; Salomon, D; van den Bergh, H; Wagnières, G; Zellweger, M, 2008)
"Etretinate-pretreated cells underwent apoptosis in response to ALA-based PDT."	1.35	Etretinate enhances the susceptibility of human skin squamous cell carcinoma cells to 5-aminolaevulic acid-based photodynamic therapy. ( Akita, Y; Ishida, N; Kuhara, T; Matsumoto, Y; Nakano, A; Takeo, T; Tamada, Y; Watanabe, D; Yamashita, N; Yanagishita, T, 2009)
"While the standard treatments for Bowen's disease (BD) (surgery, cryotherapy and antimitotic agents) are efficient, they are associated with extensive scarring."	1.35	[The value of photodynamic therapy in the treatment of Bowen's disease]. ( Bédane, C; Bonnetblanc, JM; Doffoel-Hantz, V; Durox, H; Marin, B; Sparsa, A, 2008)
"The occurrence of non-melanoma skin cancer (NMSC), including actinic keratosis (AK) is increasing all over the world."	1.35	Fluorescence detection and diagnosis of non-melanoma skin cancer at an early stage. ( Bjerring, P; de Leeuw, J; Neugebauer, WD; Neumann, HA; van der Beek, N, 2009)
"Twelve patients with Bowen's disease (eight) and superficial basal cell carcinoma (four) < 2 cm in diameter were recruited into the study following histological confirmation of the diagnosis."	1.35	An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. ( Attili, SK; Camacho-Lopez, M; Ferguson, J; Ibbotson, S; Lesar, A; McNeill, A; Moseley, H; Samuel, ID, 2009)
"In the present study, five patients with extramammary Paget's disease with a total of eight lesions first underwent carbon dioxide (CO2) laser abrasion, followed by 3 h of occlusive application of aminolaevulinic acid (ALA) and then 100 J/cm2 irradiation with a 630-nm excimer dye laser."	1.35	Photodynamic therapy following carbon dioxide laser enhances efficacy in the treatment of extramammary Paget's disease. ( Fukui, T; Matsumoto, Y; Tamada, Y; Watanabe, D, 2009)
"They included squamous cell carcinoma (SCC), basal cell carcinoma (BCC), Bowen's disease (BD), mammary and extramammary Paget disease, actinic keratosis (AK) and erythroplasia of Queyrat."	1.35	Treatment of skin cancer and pre-cancer using topical ALA-PDT--a single hospital experience. ( Guo, MX; Wang, HW; Wang, XL; Xu, SZ, 2008)
"So far, we have treated 76 cases of skin cancer and pre-cancer using topical ALA-PDT."	1.35	Treatment of skin cancer and pre-cancer using topical ALA-PDT--a single hospital experience. ( Guo, MX; Wang, HW; Wang, XL; Xu, SZ, 2008)
"5-aminolevulinic acid heptyl ester was investigated in human adenocarcinoma WiDr cells and in healthy skin of athymic nude mice in comparison with 5-aminolevulinic acid (ALA)."	1.35	A comparison of 5-aminolaevulinic acid- and its heptyl ester: dark cytotoxicity and protoporphyrin IX synthesis in human adenocarcinoma WiDr cells and in athymic nude mice healthy skin. ( Iani, V; Juzeniene, A; Ma, LW; Moan, J; Pudroma, X, 2009)
"The concept of skin cancer prevention with photodynamic therapy has evolved over the past few years to include large surface application of aminolevulinic acid or methyl aminolevulinate followed by light exposure to prevent the development of new lesions."	1.34	Chemopreventative thoughts for photodynamic therapy. ( Bissonnette, R, 2007)
"Cutaneous verrucous carcinoma is a low-grade and well-differentiated variant of squamous cell carcinoma."	1.34	Photodynamic therapy for cutaneous verrucous carcinoma. ( Nikkels, AF; Piérard, GE; Quatresooz, P; Thirion, L, 2007)
"Melanotic melanomas have a poor response to photodynamic therapy (PDT)."	1.34	A new method for photodynamic therapy of melanotic melanoma -- effects of depigmentation with violet light photodynamic therapy. ( Iani, V; Ma, LW; Moan, J; Nielsen, KP, 2007)
" For laser treatments, a sigmoidal light dose-response relationship predicted more than 85% initial response rates for light doses 150 J/cm(2) or more."	1.33	Treatment of diffuse basal cell carcinomas and basaloid follicular hamartomas in nevoid basal cell carcinoma syndrome by wide-area 5-aminolevulinic acid photodynamic therapy. ( Bellnier, DA; Blumenson, LE; Cheney, R; Frawley, NP; Oseroff, AR; Pivnick, EK; Shieh, S, 2005)
"The mean area of the patches of Bowen's disease was 315."	1.33	Investigation of the use of the pulsed dye laser in the treatment of Bowen's disease using 5-aminolaevulinic acid phototherapy. ( Britton, JE; Goulden, V; Sheehan-Dare, R; Stables, G; Stringer, M, 2005)
" This approach makes ALA dosing difficult and delivery to demanding areas, such as the vulval, perineal and perianal skin, are seldom possible."	1.33	Design and evaluation of a water-soluble bioadhesive patch formulation for cutaneous delivery of 5-aminolevulinic acid to superficial neoplastic lesions. ( Donnelly, RF; McCarron, PA; Woolfson, AD; Zawislak, A, 2006)
"Exclusion of unilateral nevoid basal cell carcinoma syndrome is indicated."	1.33	Unilateral Basal cell carcinomas: an unusual entity treated with photodynamic therapy. ( Allen, JH; Lane, JE; Lane, TN; Lesher, JL, 2005)
"Like nevoid basal cell carcinoma syndrome, unilateral basal cell carcinomas poses a therapeutic challenge with the sheer number of cutaneous tumors."	1.33	Unilateral Basal cell carcinomas: an unusual entity treated with photodynamic therapy. ( Allen, JH; Lane, JE; Lane, TN; Lesher, JL, 2005)
" An approach to improve the bioavailability of protoporphyrin IX (PpIX) is the use of ALA derivatives instead of ALA."	1.32	Topical application of ALA and ALA hexyl ester on a subcutaneous murine mammary adenocarcinoma: tissue distribution. ( Batlle, A; Casas, A; Fukuda, H; Perotti, C; Sacca, P, 2003)
"Depth of treatment of skin cancers were increased in CaNa2 EDTA-treated group."	1.32	Influence of CaNa2 EDTA on topical 5-aminolaevulinic acid photodynamic therapy. ( Liu, HF; Xu, SZ; Zhang, CR, 2004)
"Aminolevulinic acid (ALA) is a charged, hydrophilic molecule that penetrates poorly through cellular structures."	1.32	Evaluation of the penetration of 5-aminolevulinic acid through basal cell carcinoma: a pilot study. ( Ahmadi, S; Donnelly, RF; McCarron, PA; McKenna, K; Woolfson, AD, 2004)
"5-aminolevulinic acid (5-ALA) is a precursor in synthesis of endogenous porphyrins used to sensitize tumor tissues in photodynamic therapy (PDT)."	1.32	Enhancement of photodynamic therapy by use of aminolevulinic acid/glycolic acid drug mixture. ( Bronowicz, A; Oremek, G; Osiecka, BJ; Saleh, Y; Siewinski, M; Symonowicz, K; Ziolkowski, P, 2004)
"It is a new alternative modality for skin cancer therapies."	1.31	Evaluation of photodynamic therapy of skin cancers with partial differential alpha-aminolevulinic acid. ( Wang, X; Xia, Y; Xu, S; Xu, W; Zhang, C, 2002)
"A total of 13 squamous cell carcinomas were treated, including 10 nasal planum lesions, two pinnal lesions and one eyelid lesion."	1.31	Photodynamic therapy of feline superficial squamous cell carcinoma using topical 5-aminolaevulinic acid. ( Dobson, JM; Langmack, K; Stell, AJ, 2001)
"Large patches of Bowen's disease (intraepidermal carcinoma in situ) can be difficult to treat by conventional methods."	1.30	Large patches of Bowen's disease treated by topical aminolaevulinic acid photodynamic therapy. ( Ash, DV; Robinson, DJ; Stables, GI; Stringer, MR, 1997)
"The two principal locations of the 10 Bowen's disease lesions were the leg (50%) and the trunk (40%)."	1.29	Photodynamic therapy of non-melanoma malignant tumours of the skin using topical delta-amino levulinic acid sensitization and laser irradiation. ( Andersson, T; Andersson-Engels, S; Berg, R; Johansson, J; Killander, D; Stenram, U; Svanberg, K; Svanberg, S; Wang, I, 1994)
"Ten basal cell carcinomas were coated with an ointment containing 10% ALA prior to excision; five served as controls."	1.29	Penetration potency of topical applied delta-aminolevulinic acid for photodynamic therapy of basal cell carcinoma. ( Landthaler, M; Sassy, T; Szeimies, RM, 1994)

Research

Studies (636)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

Lesion Complete Response Assessed 12 Weeks After the Last PDT

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.16)	18.7374
1990's	72 (11.32)	18.2507
2000's	205 (32.23)	29.6817
2010's	275 (43.24)	24.3611
2020's	83 (13.05)	2.80

Authors	Studies
McEwan, C	1
Nesbitt, H	1
Nicholas, D	1
Kavanagh, ON	1
McKenna, K	3
Loan, P	1
Jack, IG	1
McHale, AP	1
Callan, JF	1
Ibbotson, SH	10
Ferguson, J	8
Moseley, H	11
Samuel, IDW	2
Lesar, A	4
Dawe, RS	2
Liao, C	4
Shi, L	9
Wang, D	3
Wang, X	28
Lv, T	5
Huang, J	1
Wu, M	2
Wang, H	5
Zeng, Q	6
George, A	1
Shrivastav, PS	1
Salvio, AG	6
Veneziano, DB	1
Moriyama, LT	3
Inada, NM	2
Grecco, C	1
Kurachi, C	6
Bagnato, VS	8
Condorelli, AG	1
Motolese, A	2
Borgia, F	1
Bartolomeo, LD	1
Bianchi, L	1
Rossi, PG	1
Ottone, M	1
Guarneri, F	1
Yang, Z	1
Feng, Y	1
Li, D	2
Pang, Z	1
Wang, S	3
Chen, H	1
Jiang, M	1
Yan, H	1
Li, T	1
Fu, H	1
Xiong, H	1
Shi, D	1
Fang, S	2
Wu, Y	3
Zhang, H	7
Wang, P	15
Zhang, L	15
Yan, G	3
Zhang, G	14
van Delft, LCJ	2
Nelemans, PJ	8
Kessels, JPHM	2
Kreukels, H	2
Roozeboom, MH	8
de Rooij, MJM	1
Mosterd, K	12
de Haas, ERM	2
Kelleners-Smeets, NWJ	4
Sun, S	1
Yin, R	1
Zhang, P	2
Jiang, R	1
Xiao, C	1
Cheng, B	1
Veerabagu, S	1
Miller, CJ	1
Sobanko, JF	1
Shin, TM	1
Higgins, HW	1
Giordano, CN	1
Etzkorn, JR	2
Nicolás-Morala, J	1
Portillo-Esnaola, M	1
Terrén, S	1
Gutiérrez-Pérez, M	1
Gilaberte, Y	11
González, S	8
Juarranz, Á	7
Ye, T	2
Yang, L	3
Liu, X	9
Jiang, B	2
Chen, B	2
Zou, Y	3
Yu, B	2
Yang, W	2
Liu, L	1
Adnane, F	1
El-Zayat, E	1
Fahmy, HM	1
Schary, N	1
Novak, B	3
Kämper, L	1
Yousf, A	1
Lübbert, H	2
Lo, TK	1
Chen, YC	1
Liu, WT	1
Wong, TW	2
Thompson, A	1
Mattia, A	1
Green, WH	2
Cognetta, AB	2
Evangelou, G	3
Koumaki, D	1
Fragiadaki, I	1
Chaniotis, V	1
Farrar, MD	3
Karatzi, C	1
Sotiriou, E	7
Giannikaki, E	1
Katoulis, A	1
Papadakis, M	1
Lallas, A	4
Stefanidou, M	1
Krueger-Krasagakis, S	1
Rhodes, LE	7
Krasagakis, K	1
Zhao, Z	4
Zhou, Z	4
Liu, Y	4
Zhang, Y	4
Ge, K	1
Zhang, R	2
Sun, Y	1
Sheng, Y	1
Bradley, M	1
Lultschik, S	1
Tran, J	1
Sapra, S	1
Sharma, K	1
Dong, K	1
Xiang, X	1
Li, Y	1
Tang, Y	2
Liu, R	1
Ma, T	1
Ma, G	1
Zhang, J	7
Feng, Q	1
Xiao, J	1
Lin, J	1
Wang, J	4
Nestor, MS	3
Han, H	1
Ceci, FM	1
Lawson, A	1
Gade, A	1
Yan, Y	1
Cao, Z	1
Wang, B	4
Chang, Q	1
Chen, C	1
Jin, S	1
Sun, X	3
Yu, J	3
Xing, W	1
Chen, D	1
Xu, S	3
Zhang, M	3
McNicholas, K	1
MacGregor, MN	1
Gleadle, JM	1
Ji, Z	2
Yang, S	1
Räsänen, JE	1
Neittaanmäki, N	2
Jeskanen, L	2
Pölönen, I	2
Snellman, E	2
Grönroos, M	2
Naidoo, C	1
Kruger, CA	1
Abrahamse, H	2
Pires, MTF	1
Pereira, AD	1
Durães, SMB	1
Issa, MCA	1
Pires, M	1
Fu, C	2
Qin, L	2
Zeng, XY	2
Wang, BC	2
Cao, D	1
Zhu, W	1
Kuang, Y	1
Zhao, S	4
Hellen, R	1
Nic Dhonncha, E	1
Havelin, A	1
Fleming, L	1
Kavanagh, A	1
Lally, A	1
Kirby, B	1
Moriarty, B	1
Collins, P	2
Gracia-Cazaña, T	5
García-Malinis, AJ	1
Kibbi, N	1
Leffell, DJ	1
Christensen, SR	1
Requena, MB	3
Russignoli, PE	1
Vollet-Filho, JD	2
Fortunato, TC	1
Pratavieira, S	2
Ferrara, F	1
Lacava, R	1
Barisani, A	1
Messori, S	1
Patrizi, A	2
Bardazzi, F	2
Vaccari, S	1
Gubarkova, EV	1
Feldchtein, FI	1
Zagaynova, EV	1
Gamayunov, SV	1
Sirotkina, MA	1
Sedova, ES	1
Kuznetsov, SS	1
Moiseev, AA	1
Matveev, LA	1
Zaitsev, VY	1
Karashtin, DA	1
Gelikonov, GV	1
Pires, L	2
Vitkin, A	1
Gladkova, ND	1
Che, Q	1
Li, J	5
Wang, Q	1
Jiang, L	1
Li, Z	3
Liu, H	1
Zeng, K	1
Ma, J	1
Liu, Q	1
Garcia, MR	1
Becker, M	1
Magalhães, DV	1
Logan, IT	1
Kulakov, EL	1
Perrett, CM	3
Chaabani, M	1
Ben Lagha, I	1
Ben Tanfous, A	1
Koubaa, W	1
Ben Brahim, E	1
Fenniche, S	1
Zaouak, A	1
Hammami-Ghorbel, H	1
Filonenko, E	1
Kaprin, A	1
Urlova, A	1
Grigorievykh, N	1
Ivanova-Radkevich, V	1
Stringasci, MD	2
Barreto Requena, M	1
Dong, L	1
Li, X	4
Shen, X	1
Zhang, W	1
Wang, Y	9
Lu, Y	6
Darr-Foit, S	1
Elsner, P	1
Goetze, S	1
Salmivuori, M	1
Tani, T	1
Räsänen, J	1
Annala, L	1
Fonda-Pascual, P	1
Fernandez-Gonzalez, P	2
Sanchez-Los Arcos, L	1
Alcantara-Nicolas, F	1
Lopez-Galan, C	1
Canseco-Martin, M	1
Vidal-Asensi, S	1
Stephens, R	1
Holmes, J	1
Eadie, E	2
Wu, MF	1
Wang, HW	3
Fan, H	1
Hu, Z	1
Wu, W	1
Geng, H	1
León, D	1
Buchegger, K	1
Silva, R	1
Riquelme, I	1
Viscarra, T	1
Mora-Lagos, B	1
Zanella, L	1
Schafer, F	1
Roa, JC	1
Ili, C	1
Brebi, P	1
Govindjee, G	1
Briskin, DP	1
Benning, C	1
Daniell, H	1
Kolossov, V	1
Scheer, H	1
Rebeiz, M	1
Piacquadio, D	1
Houlihan, A	1
Ferdon, MB	1
Berg, JE	1
Marcus, SL	2
Kapek, Ł	1
Cholewka, A	3
Szurko, A	1
Sieroń, K	1
Sieroń, A	1
Kwiatek, S	2
Stanek, A	2
Woźniak, Z	1
Trzeciakowski, W	1
Chlebicka, I	1
Ziółkowski, P	2
Miller, MB	1
Padilla, A	1
Repelnig, ML	1
Weger, W	1
Cerpes, U	1
Wolf, P	12
Legat, FJ	2
Queirós, C	1
Garrido, PM	1
Maia Silva, J	1
Filipe, P	2
Zhang, GL	1
Keyal, U	3
Wang, PR	1
Zhang, LL	2
Bhatta, AK	4
Wu, YH	1
Wang, XL	3
Zhang, X	4
Yang, Y	8
Kou, H	2
Yan, J	1
Li, L	2
Zhao, W	1
Zheng, B	1
Chen, T	1
De Luca, EV	1
Tambone, S	1
Catapano, S	1
Fossati, B	1
Peris, K	3
Thomson, J	1
Hogan, S	1
Leonardi-Bee, J	2
Williams, HC	1
Bath-Hextall, FJ	2
Navarro-Triviño, FJ	1
Ayén-Rodríguez, Á	1
Llamas-Molina, JM	1
Saenz-Guirado, S	1
Ruiz-Villaverde, R	1
Szeimies, RM	17
Karrer, S	4
Pierre, MBR	1
Heron, CE	1
Feldman, SR	1
Liu, D	2
Chen, M	2
Wu, L	2
Gómez, C	2
Cobos, P	1
Alberdi, E	2
Nicolás, J	1
Cerro-Muñoz, PA	1
Severson, KJ	1
Cumsky, HJL	1
Brumfiel, CM	1
Janeczek, MC	1
Ginos, BF	1
Kosiorek, HE	1
Besch-Stokes, J	1
Patel, MH	1
Rule, WG	1
DiCaudo, DJ	1
Rosenthal, AC	1
Pittelkow, MR	1
Mangold, AR	1
Azzopardi, EA	1
Abdelrahman, W	1
Azzopardi, E	1
O'Leary, B	2
Yarrow, J	1
Miles, N	1
Barbara, C	1
Camilleri, L	1
Clementoni, MT	1
Murison, M	2
Juan-Carpena, G	1
Palazón-Cabanes, JC	1
Blanes-Martínez, M	1
Luan, S	1
Tran, NT	1
Xue, HY	1
Wong, HL	1
O'Mahoney, P	1
Ibbotson, S	11
Zhu, L	4
Zhao, Y	4
Hu, C	1
Yu, N	2
Luo, X	3
Wei, T	1
Zhang, Q	2
Su, J	1
Huang, K	1
Li, F	1
Xie, Y	1
Fang, F	3
He, R	1
Chen, X	4
Bu, W	3
Peng, J	1
Feng, W	1
Wang, T	2
Xiang, W	1
Dai, Y	1
Zhu, J	2
Zheng, J	1
Canavan, TN	1
de la Feld, SF	1
Huang, C	1
Sami, N	1
Gao, Y	4
Wang, WS	2
Wang, HL	2
Liu, J	4
Lu, YG	3
Essers, BAB	2
Arits, AH	6
Hendriks, MR	1
Kelleners-Smeets, NW	9
Manno, K	1
Cohen, JL	2
van Pelt, H	1
Salazar, N	2
Vera-Álvarez, J	3
Aguilera, J	1
López-Navarro, N	1
Herrera-Ceballos, E	1
Wan, M	1
Ma, H	1
Xie, L	1
Chen, Z	1
Jansen, MHE	2
Arits, AHMM	2
Sommer, A	2
van Pelt, HPA	1
Quaedvlieg, PJF	1
Steijlen, PM	4
Rizzo, JM	1
Segal, RJ	1
Zeitouni, NC	5
JalalKamali, M	1
Nematollahi-Mahani, SN	1
Shojaei, M	1
Shamsoddini, A	1
Arabpour, N	1
Zhang, S	2
Yu, R	1
Hu, N	1
Suárez Valladares, MJ	2
Vega, J	1
Rodríguez Prieto, MA	3
Shaw, FM	1
Weinstock, MA	1
Morton, CA	13
Dominicus, R	1
Radny, P	1
Dirschka, T	2
Hauschild, A	1
Reinhold, U	1
Aschoff, R	1
Ulrich, M	1
Keohane, S	1
Ekanayake-Bohlig, S	1
Ostendorf, R	1
Berking, C	2
Gröne, D	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Randomized, Observer Blind, Multinational Phase III Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) in Comparison to Metvix® in the Treatment of Non-aggressive Basal Cell Carcinoma (BCC) With Photodynamic Therapy (PDT)[NCT02144077]	Phase 3	281 participants (Actual)	Interventional	2014-01-28	Completed
Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease: a Multicenter Randomized Controlled Trial[NCT03909646]	Phase 4	250 participants (Anticipated)	Interventional	2019-05-27	Recruiting
Fluorescence and Thermal Imaging of the Skin Before and During Photodynamic Therapy[NCT03167762]		18 participants (Actual)	Interventional	2017-06-22	Completed
A Randomised Trial Comparing Methyl Aminolaevulinate Photodynamic Therapy With and Without Ablative Fractional Laser Treatment in Patients With Microinvasive Squamous Cell Carcinoma: Results From a 24-month Follow-up[NCT02666534]	Phase 1	45 participants (Actual)	Interventional	2012-01-31	Completed
Dimethylsulphoxide-supported Photodynamic Therapy of Basal Cell Carcinoma Combined With Curettage - A 6 Year Clinical and Histological Evaluation.[NCT00218829]		44 participants (Actual)	Observational	1997-09-30	Completed
A Randomized Assessor-blinded Comparison of Low Irradiance and Conventional Irradiance Photodynamic Therapy (PDT) for Superficial Non-melanoma Skin Cancer[NCT02872909]		50 participants (Actual)	Interventional	2011-10-31	Completed
A Randomized Half-side Comparative Trial of Fractional Laser-assisted Daylight Photodynamic Therapy Versus Daylight Photodynamic Therapy in Organ Transplant Recipients With Multiple Actinic Keratoses of the Scalp or Forehead[NCT01898936]		12 participants (Actual)	Interventional	2013-08-31	Completed
Indoor Daylight Photo Dynamic Therapy (PDT) for Actinic Keratosis[NCT03805737]		43 participants (Actual)	Interventional	2019-11-01	Completed
Portable Measurement of Protoporphyrin IX in the Skin[NCT04223570]		218 participants (Anticipated)	Observational	2022-12-01	Enrolling by invitation
A Single Center Phase II Trial of Vemurafenib (R05185426) in Poor Performance Status Patients With Unresectable Locally Advanced or Metastatic Melanoma Harboring a V600E/K Mutation[NCT01474551]	Phase 2	2 participants (Actual)	Interventional	2011-11-30	Terminated (stopped due to Lack of accrual)
Topical Imiquimod 5% Cream Therapy Versus Photodynamic Therapy With Methyl-aminolaevulinate 16% Cream of Actinic Keratoses in Organ Transplant Recipients[NCT01538901]	Phase 4	10 participants (Actual)	Interventional	2012-09-30	Terminated (stopped due to prolonged recruitment phase)
Interferon Alpha Therapy for Cervical CIN I and HPV Infection[NCT06137950]	Phase 1	90 participants (Anticipated)	Interventional	2023-11-07	Recruiting
Evaluation of the Formulation of 5-aminolevulinic Acid With Dimethylsulfoxide in Photodynamic Therapy for Treatment of Actinic Keratosis[NCT01459393]	Phase 3	137 participants (Actual)	Interventional	2010-11-30	Completed
Photodynamic Therapy for Treatment of Cutaneous Squamous Cell Carcinoma in Situ[NCT03025724]		40 participants (Anticipated)	Interventional	2017-01-31	Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Lesion complete response (completely cleared individual lesions) assessed 12 weeks after the last PDT. The indicated values give percentage of overall completely cleared individual lesions. The PP set is the primary analysis set for the analysis of the secondary endpoint. (NCT02144077)
Timeframe: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).

Overall Patient Complete Response Rate Assessed 12 Weeks After the Last PDT

Intervention	Percentage of Individual Lesions (Number)
BF-200 ALA	94.6
Methyl-aminolevulinate	92.9

Overall patient complete response rate assessed 12 weeks after the last PDT. The indicated values give the percentage of overall complete responders. An overall complete responder is defined as a patient in whom all treated lesions were cleared. The PP set is the primary analysis set for the analyses of the primary endpoint. (NCT02144077)
Timeframe: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).

Patient Complete Response 12 Weeks After PDT-2

Intervention	Percentage of Patients (Number)
BF-200 ALA	93.4
Methyl-aminolevulinate	91.8

Patient complete response (complete clearance of all treated lesions) assessed 12 weeks after PDT-2 (first PDT cycle). The PP set is the primary analysis set for the analysis of the secondary endpoint. (NCT02144077)
Timeframe: 12 weeks after PDT-2 (=PDT cycle 1; please note: in this study 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).

Patient Recurrence Rate (Overall, Cumulative)

Intervention	Percentage of Patients (Number)
BF-200 ALA	57.9
Methyl-aminolevulinate	56.4

Patient recurrence rate defined as the number of patients with at least one recurrent lesion during FU after complete clearance 12 weeks after the last PDT (NCT02144077)
Timeframe: 6, 12, 24, 36 and 60 months post-PDT

Reduction of Lesion Area 12 Weeks After the Last PDT Compared to Baseline

Intervention	percentage of patients (cumulative) (Number)
BF-200 ALA	16.9
Methyl-aminolevulinate	15.5

"Reduction of total lesion area (summation of sizes of all treated lesions) per patient, assessed 12 weeks after the last PDT. The PP set is the primary analysis set for the analysis of the secondary endpoint.~Please note that the high SD for BF-200 ALA is due to a patient who had increased lesion area fom 63 mm² at baseline to 225 mm² 12 weeks after PDT. This lesion area included a lesion that was later confirmed to be benign skin condition (lentigo solaris)." (NCT02144077)
Timeframe: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).

Cosmetic Outcome 12 Weeks After Last PDT (Including Patients With a Sum Score of 0 at Baseline)

Intervention	Percentage of Change (Mean)
BF-200 ALA	-94.5
Methyl-aminolevulinate	-97.0

"Overall cosmetic outcome 12 weeks after last PDT is calculated as difference between 12 weeks after PDT sum score and baseline sum score of all skin quality assessments. Each of the below skin quality characteristics are assessed on a 4-point scale from 0 (none) to 3 (severe) by the investigator at baseline and 12 weeks after last PDT:~Skin surface~Hyperpigmentation~Hypopigmentation~Mottled or irregular pigmentation~Degree of scarring~Atrophy~Cosmetic outcome categories are:~Very good: 12 weeks sum score improved by at least 2 points compared to baseline~Good: 12 weeks sum score improved by 1 point compared to baseline~Satisfactory: 12 weeks sum score identical to the one at baseline~Unsatisfactory: 12 weeks sum score worsened by 1 point compared to baseline~Impaired: 12 weeks sum score worsened by at least 2 points compared to baseline" (NCT02144077)
Timeframe: 12 weeks after the last PDT (please note: 2 PDT cycles, each cycle consisting of 2 PDTs (= maximum of 4 PDTs per patient) was possible).

Cosmetic Outcome 12 Weeks After the Last PDT (Including Patients With a Baseline Sum Score >1)

Intervention	Percentage of Patients (Number)
	Very good	Good	Satisfactory	Unsatisfactory	Impaired
BF-200 ALA	23.3	11.7	35.8	14.2	15.0
Methyl-aminolevulinate	14.7	18.3	29.4	20.2	17.4

Lesion Recurrence Rate (Cumulative)

Intervention	Percentage of Patients (Number)
	Very good	Good	Satisfactory	Unsatisfactory	Impaired
BF-200 ALA	40.0	20.0	22.9	11.4	5.7
Methyl-aminolevulinate	21.6	27.0	32.4	12.2	6.8

Lesion recurrence rate defined as the number of completely cleared lesions 12 weeks after the last PDT showing recurrence during FU. Overall and subgroup analysis (nodular basal cell carcinoma (nBCC) and superficial basal cell carcinoma (sBCC)). (NCT02144077)
Timeframe: 6, 12, 24, 36 and 60 months post-PDT

Clinical Clearance of Lesion

Intervention	percentage of lesions (cumulative) (Number)
	Overall	sBCC	nBCC
BF-200 ALA	13.5	10.3	25
Methyl-aminolevulinate	13.4	11.9	21.4

clinical assessment by study dermatologist to determine by inspection and palpation whether the lesion is clear, partially clear or not clear - assessed at 3, 6 and 12 months after treatment, with 12 months as the final study outcome endpoint analysed (NCT02872909)
Timeframe: 12 months after treatment

Pain on VAS Score

Intervention	Participants (Count of Participants)
Low Irradiance LED PDT	27
Conventional Higher Irradiance LED	14

assess on visual analogue scale (VAS) score of 0 - 10cm, with 0 representing no pain experienced through to 10 representing the worst pain imaginable. The participant marks across a 0-10cm unmarked line where their level of pain experience is and this is measured eg. 2cm if experiencing mild pain or 8.5cm which would represent severe pain (NCT02872909)
Timeframe: one week after treatment

Patient Satisfaction

Intervention	score on a scale (Median)
Low Irradiance LED PDT	2.95
Conventional Higher Irradiance LED	1.25

"brief patient questionnaire to evaluate their opinion of the treatment they received. This is assessed as A.efficacy of treatment - 1 = not effective NR; 2 = partIally effective PR; 3 = completely effective CR; B.Side effects of treatment eg. pain and inflammation - 1 = severe; 2 = moderate; 3 = mild; 4 = none/minimal. C.Practicalities of treatment eg. ease of use, travel, time, inconvenience - 1 = very disruptive and difficult; 2 = moderately disruptive and difficult; 3 = minimally disruptive and difficult. The scores of A, B and C will be added to give an overall score with range of overall minimum score option 3 and maximum 10.~Patients will also separately be asked to give overall evaluation on a VAS scale of 0 = treatment very poor and would not have again through to 10 = treatment excellent and I would have again - with a continuous line option from 0 - 10 to mark across, providing a separate score with range options 0 to 10" (NCT02872909)
Timeframe: one year after treatment - last visit

Phototoxicity

Intervention	score on a scale (Median)
Low Irradiance LED PDT	10
Conventional Higher Irradiance LED	10

"erythema, oedema, blistering, crusting, ulceration on semi-quantitative scale. Erythema is graded as 0 = absent, 1 = mild, 2 = moderate or 3 = severe erythema as assessed by naked eye examination. Oedema is graded as 0 = absent or 1 = present. Likewise crusting or ulceration are each graded as 0 = absent and 1 = present by naked eye examination. Data will be presented and analysed separately ie. erythema data will be presented and then separately whether oedema, crusting or ulceration are present or absent.~ie. reporting may appear as example: erythema score 3 of range of 0-3 options; oedema score 1 (binary option of 0 or 1); crusting score 0 (binary option of 0 or 1); ulceration score 0 (binary option of 0 or 1)" (NCT02872909)
Timeframe: one week after treatment

Overall Objective Response

Intervention	score on a scale (Median)
Low Irradiance LED PDT	2
Conventional Higher Irradiance LED	1

The Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 will be used to determine treatment response. In order to be considered evaluable for response, a patient must have completed at least 1 cycle of therapy. Patients who do not complete a cycle of therapy can be replaced. (NCT01474551)
Timeframe: 2 years

Intervention	participants (Number)
	Stable Disease	Complete Response	Partial Response	Progression of Disease
Vemurafenib	1	0	0	0

Article	Year
Photodynamic therapy with light emitting fabrics: a review. Archives of dermatological research, 2022, Volume: 314, Issue:10 Topics: Aminolevulinic Acid; Bowen's Disease; Humans; Oxygen; Photochemotherapy; Photosensitizing Agents; Sk	2022
The combinational application of photodynamic therapy and nanotechnology in skin cancer treatment: A review. Tissue & cell, 2022, Volume: 77 Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Nanotechnology; Photochemotherapy; Skin Neoplasms	2022
In order for the light to shine so brightly, the darkness must be present-why do cancers fluoresce with 5-aminolaevulinic acid? British journal of cancer, 2019, Volume: 121, Issue:8 Topics: Amino Acid Transport Systems; Aminolevulinic Acid; Brain Neoplasms; Coproporphyrinogens; Ferrochelat	2019
Simultaneous Photodiagnosis and Photodynamic Treatment of Metastatic Melanoma. Molecules (Basel, Switzerland), 2019, Aug-29, Volume: 24, Issue:17 Topics: Aminolevulinic Acid; Anthracenes; Biopsy, Fine-Needle; Drug Carriers; Early Diagnosis; Humans; Indol	2019
Photodynamic therapy with methyl-5-aminolevulinate for basal cell carcinoma: A systematic review and meta-analysis. Photodiagnosis and photodynamic therapy, 2020, Volume: 29 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Skin	2020
Photodynamic therapy in dermatology: Beyond current indications. Dermatologic therapy, 2020, Volume: 33, Issue:6 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Dermatology; Humans; Keratosis, Actinic; Photochemothera	2020
Interventions for basal cell carcinoma of the skin. The Cochrane database of systematic reviews, 2020, 11-17, Volume: 11 Topics: Adult; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Basal Cell; Cryotherapy; Female; Human	2020
[Photodynamic therapy-trends and new developments]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2021, Volume: 72, Issue:1 Topics: Aminolevulinic Acid; Bowen's Disease; Humans; Keratosis, Actinic; Photochemotherapy; Photosensitizin	2021
Nanocarriers for Photodynamic Therapy Intended to Cutaneous Tumors. Current drug targets, 2021, Volume: 22, Issue:10 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Drug Carriers; Humans; Nanoparticles; P	2021
The application of physical pretreatment in photodynamic therapy for skin diseases. Lasers in medical science, 2021, Volume: 36, Issue:7 Topics: Aminolevulinic Acid; Humans; Keratosis, Actinic; Neoplasm Recurrence, Local; Photochemotherapy; Phot	2021
Photodynamic therapy as an alternative treatment for mycosis fungoides: a systemic review and meta-analysis. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2018, Volume: 153, Issue:6 Topics: Aminolevulinic Acid; Humans; Mycosis Fungoides; Neoplasm Staging; Photochemotherapy; Photosensitizin	2018
Pain perception during photodynamic therapy: why is daylight PDT with methyl aminolevulinate almost pain-free? A review on the underlying mechanisms, clinical reflections and resulting opportunities. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2018, Volume: 153, Issue:6 Topics: Aminolevulinic Acid; Humans; Light; Pain; Pain Perception; Photochemotherapy; Photosensitizing Agent	2018
Daylight photodynamic therapy for field cancerization: lessons from molecular biology. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2018, Volume: 153, Issue:6 Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Humans; Keratosis, Actinic; Light; Pain; Photochemoth	2018
An update on topical photodynamic therapy for clinical dermatologists. The Journal of dermatological treatment, 2019, Volume: 30, Issue:8 Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Dermatologists; Humans; Light;	2019
Photodynamic therapy for skin cancer: How to enhance drug penetration? Journal of photochemistry and photobiology. B, Biology, 2019, Volume: 197 Topics: Aminolevulinic Acid; Drug Compounding; Humans; Liposomes; Micelles; Nanoparticles; Photochemotherapy	2019
Photodynamic therapy in the treatment of basal cell carcinoma. Journal of medicine and life, 2013, Mar-15, Volume: 6, Issue:1 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Skin Neoplasms	2013
Interventions for cutaneous Bowen's disease. The Cochrane database of systematic reviews, 2013, Jun-24, Issue:6 Topics: Aminolevulinic Acid; Aminoquinolines; Antineoplastic Agents; Bowen's Disease; Cryotherapy; Fluoroura	2013
Current methods for photodynamic therapy in the US: comparison of MAL/PDT and ALA/PDT. Journal of drugs in dermatology : JDD, 2013, Volume: 12, Issue:8 Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Disease Progression; Humans; Keratosis, Actinic; Phot	2013
Photodynamic therapy with methyl-aminolevulinic acid for paucilesional mycosis fungoides: a prospective open study and review of the literature. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:6 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Male; Middle Aged; Mycosis Fungoides;	2013
[PDT panoramic view. Principle, photosensitizers, light sources and validated indications in dermatology]. Annales de dermatologie et de venereologie, 2013, Volume: 140 Suppl 2 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Clinical Trials as Topic; Humans; Kerat	2013
Usefulness of Photodynamic Therapy as a Possible Therapeutic Alternative in the Treatment of Basal Cell Carcinoma. International journal of molecular sciences, 2015, Sep-28, Volume: 16, Issue:10 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Neoplasm Staging; Photochemotherapy; Skin Neopla	2015
Translational medicine in the field of ablative fractional laser (AFXL)-assisted drug delivery: A critical review from basics to current clinical status. Journal of the American Academy of Dermatology, 2016, Volume: 74, Issue:5 Topics: Administration, Cutaneous; Aminolevulinic Acid; Anesthetics; Animals; Cicatrix; Controlled Clinical	2016
Photodynamic therapy versus surgical excision to basal cell carcinoma: meta-analysis. Journal of cosmetic dermatology, 2016, Volume: 15, Issue:4 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Neoplasm Recurrence, Local; Photochemotherapy; P	2016
Photodynamic therapy as an alternative treatment for relapsed or refractory mycosis fungoides: A systemic review. Photodiagnosis and photodynamic therapy, 2017, Volume: 17 Topics: Aminolevulinic Acid; Humans; Mycosis Fungoides; Photochemotherapy; Photosensitizing Agents; Skin Neo	2017
Ameluz for actinic keratoses. The Medical letter on drugs and therapeutics, 2016, Dec-05, Volume: 58, Issue:1509 Topics: Administration, Topical; Aminolevulinic Acid; Drug Compounding; Erythema; Gels; Humans; Keratosis, A	2016
Photodynamic therapy for dermatologic conditions in the pediatric population: a literature review. Photodermatology, photoimmunology & photomedicine, 2017, Volume: 33, Issue:3 Topics: Acne Vulgaris; Adolescent; Aminolevulinic Acid; Child; Child, Preschool; Humans; Infant; Infant, New	2017
Optimizing ALA-PDT in the management of non-melanoma skin cancer by fractionated illumination. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2009, Volume: 144, Issue:4 Topics: Aminolevulinic Acid; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Photochemothera	2009
Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. Journal of the European Academy of Dermatology and Venereology : JEADV, 2010, Volume: 24, Issue:5 Topics: Aminolevulinic Acid; Humans; Photochemotherapy; Photosensitizing Agents; Practice Guidelines as Topi	2010
A critical reappraisal of off-label indications for topical photodynamic therapy with aminolevulinic acid and methylaminolevulinate. Reviews on recent clinical trials, 2010, Volume: 5, Issue:2 Topics: Aminolevulinic Acid; Humans; Photochemotherapy; Rejuvenation; Skin Diseases; Skin Neoplasms	2010
Intralesional agents in the management of cutaneous malignancy: a review. Journal of the American Academy of Dermatology, 2011, Volume: 64, Issue:2 Topics: Aminolevulinic Acid; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bleomycin; Carci	2011
A review of pain experienced during topical photodynamic therapy--our experience in Dundee. Photodiagnosis and photodynamic therapy, 2011, Volume: 8, Issue:1 Topics: Administration, Topical; Aminolevulinic Acid; Comorbidity; Female; Humans; Male; Pain; Pain Measurem	2011
Nonmelanoma skin cancer chemoprevention. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2011, Volume: 37, Issue:11 Topics: Acitretin; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carc	2011
Photodynamic therapy: current evidence and applications in dermatology. Seminars in cutaneous medicine and surgery, 2011, Volume: 30, Issue:4 Topics: Acne Vulgaris; Aminolevulinic Acid; Bowen's Disease; Candidiasis; Carcinoma, Basal Cell; Humans; Ker	2011
[Fluorescence diagnosis of non-melanoma skin cancer]. Orvosi hetilap, 2012, Aug-26, Volume: 153, Issue:34 Topics: Aminolevulinic Acid; Apoptosis; Carcinoma, Basal Cell; Carcinoma, Basosquamous; Carcinoma, Squamous	2012
Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clinical and experimental dermatology, 2002, Volume: 27, Issue:6 Topics: Aminolevulinic Acid; Breast Neoplasms; Female; Humans; Lymphoma, T-Cell, Cutaneous; Middle Aged; Pho	2002
Metvix (PhotoCure). Current opinion in investigational drugs (London, England : 2000), 2002, Volume: 3, Issue:11 Topics: Administration, Topical; Aminolevulinic Acid; Animals; Clinical Trials as Topic; Humans; Ointments;	2002
Photodynamic therapy for nonmelanoma skin cancers. Current review and update. Molecular immunology, 2003, Volume: 39, Issue:17-18 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Dihematoporph	2003
The role of light in the treatment of non-melanoma skin cancer using methyl aminolevulinate. The Journal of dermatological treatment, 2003, Volume: 14 Suppl 3 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Photochemotherapy; Ski	2003
Clinical efficacy of methyl aminolevulinate (Metvix) photodynamic therapy. The Journal of dermatological treatment, 2003, Volume: 14 Suppl 3 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials, Phase III as	2003
Methyl aminolevulinate (Metvix) photodynamic therapy - practical pearls. The Journal of dermatological treatment, 2003, Volume: 14 Suppl 3 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Photochemotherapy; Pra	2003
Topical and light-based treatments for actinic keratoses. Seminars in cutaneous medicine and surgery, 2003, Volume: 22, Issue:3 Topics: Adjuvants, Immunologic; Administration, Topical; Aminolevulinic Acid; Aminoquinolines; Antineoplasti	2003
Photodynamic therapy of skin cancer: controlled drug delivery of 5-ALA and its esters. Advanced drug delivery reviews, 2004, Jan-13, Volume: 56, Issue:1 Topics: Aminolevulinic Acid; Chemistry, Pharmaceutical; Drug Delivery Systems; Humans; Photochemotherapy; Ph	2004
A review of laser and photodynamic therapy for the treatment of nonmelanoma skin cancer. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2004, Volume: 30, Issue:2 Pt 2 Topics: Aminolevulinic Acid; Carcinoma in Situ; Carcinoma, Basal Cell; Clinical Trials as Topic; Humans; Ker	2004
Topical methyl aminolevulinate. American journal of clinical dermatology, 2004, Volume: 5, Issue:2 Topics: Administration, Cutaneous; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis; Photochemo	2004
delta-Aminolevulinic acid and blue light photodynamic therapy for treatment of multiple basal cell carcinomas in two patients with nevoid basal cell carcinoma syndrome. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2004, Volume: 30, Issue:7 Topics: Adult; Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Female; Humans; Middle	2004
Topical photodynamic therapy in clinical dermatology. The British journal of dermatology, 2004, Volume: 150, Issue:6 Topics: Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratosis; Phot	2004
Photodynamic therapy--a new treatment option for epithelial malignancies of the skin. Onkologie, 2004, Volume: 27, Issue:4 Topics: Aminolevulinic Acid; Humans; Neoplasms, Glandular and Epithelial; Photochemotherapy; Precancerous Co	2004
[The wider application of photodynamic therapy in dermatology]. Nederlands tijdschrift voor geneeskunde, 2005, Jan-29, Volume: 149, Issue:5 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Dermatology; Humans; Keratosis; Photoch	2005
Photodynamic therapy. The Australasian journal of dermatology, 2005, Volume: 46 Suppl 3 Topics: Administration, Topical; Aminolevulinic Acid; Antimetabolites, Antineoplastic; Cryotherapy; Fluorour	2005
Clinical efficacy of methyl aminolaevulinate photodynamic therapy in basal cell carcinoma and solar keratosis. The Australasian journal of dermatology, 2005, Volume: 46 Suppl 3 Topics: Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis; Photochemotherapy; Photosensit	2005
Topical photodynamic therapy for Bowen's disease of the digit in epidermolysis bullosa. The British journal of dermatology, 2005, Volume: 153, Issue:3 Topics: Aminolevulinic Acid; Bowen's Disease; Epidermolysis Bullosa; Female; Fingers; Humans; Middle Aged; P	2005
Photodynamic therapy in dermatology: current concepts in the treatment of skin cancer. Expert review of anticancer therapy, 2005, Volume: 5, Issue:5 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Clinical Trials as Topic; Humans; Keratosis; Photochemot	2005
[Fluorescence diagnosis in dermatology]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2003, Volume: 1, Issue:7 Topics: Aminolevulinic Acid; Image Processing, Computer-Assisted; Optical Imaging; Protoporphyrins; Skin Dis	2003
Current treatments of actinic keratosis. Journal of drugs in dermatology : JDD, 2006, Volume: 5, Issue:2 Suppl Topics: Aminolevulinic Acid; Clinical Trials as Topic; Cryosurgery; Humans; Keratosis; Photochemotherapy; Ph	2006
Fluorescence diagnosis and photodynamic therapy in dermatology from experimental state to clinic standard methods. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2006, Volume: 25, Issue:1-2 Topics: Aminolevulinic Acid; Fluorescence; Humans; Keratosis; Light; Photochemotherapy; Photosensitizing Age	2006
[Photodynamic therapy in dermatology]. Actas dermo-sifiliograficas, 2006, Volume: 97, Issue:2 Topics: Aminolevulinic Acid; Esthetics; Forecasting; Humans; Infrared Rays; Low-Level Light Therapy; Photoch	2006
Aminolevulinic acid photodynamic therapy: medical evidence for its expanded use. Expert review of medical devices, 2006, Volume: 3, Issue:3 Topics: Aminolevulinic Acid; Antineoplastic Agents; Clinical Trials as Topic; Europe; Evidence-Based Medicin	2006
Photodynamic therapies: principles and present medical applications. Bio-medical materials and engineering, 2006, Volume: 16, Issue:4 Suppl Topics: Aminolevulinic Acid; Bowen's Disease; Clinical Trials as Topic; Humans; Light; Lipoproteins, LDL; Ma	2006
Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatology, photoimmunology & photomedicine, 2006, Volume: 22, Issue:5 Topics: Administration, Cutaneous; Adult; Aged; Aminolevulinic Acid; Female; Humans; Lymphoma, T-Cell, Cutan	2006
Aminolevulinic acid photodynamic therapy for skin cancers. Dermatologic clinics, 2007, Volume: 25, Issue:1 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Photo	2007
Methyl aminolevulinate: actinic keratoses and Bowen's disease. Dermatologic clinics, 2007, Volume: 25, Issue:1 Topics: Aminolevulinic Acid; Bowen's Disease; Facial Dermatoses; Humans; Keratosis; Photochemotherapy; Photo	2007
Methyl aminolevulinate-photodynamic therapy for basal cell carcinoma. Dermatologic clinics, 2007, Volume: 25, Issue:1 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Skin	2007
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. Journal of the American Academy of Dermatology, 2007, Volume: 56, Issue:1 Topics: Aminolevulinic Acid; Australia; Basal Cell Nevus Syndrome; Bowen's Disease; Carcinoma, Basal Cell; C	2007
Aminolevulinic acid and photodynamic combination therapy in the treatment of actinic keratoses: caring for the patient. Dermatology nursing, 2007, Volume: 19, Issue:1 Topics: Aminolevulinic Acid; Heme; Humans; Keratosis; Nurse's Role; Nursing Assessment; Photochemotherapy; P	2007
Photodynamic therapy: update 2006. Part 2: Clinical results. Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:4 Topics: Aminolevulinic Acid; Drug Approval; Humans; Photochemotherapy; Photosensitizing Agents; Randomized C	2007
Methyl aminolaevulinate-photodynamic therapy: a review of clinical trials in the treatment of actinic keratoses and nonmelanoma skin cancer. The British journal of dermatology, 2007, Volume: 156, Issue:5 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis; Photochemotherapy; P	2007
Topical 5-aminolevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides: a report of two cases and review of the literature. International journal of dermatology, 2008, Volume: 47, Issue:4 Topics: Administration, Topical; Adult; Aminolevulinic Acid; Female; Humans; Low-Level Light Therapy; Male;	2008
Photodynamic therapy of primary skin cancer: a review. British journal of plastic surgery, 1995, Volume: 48, Issue:6 Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Bowen's Disease; Carcinoma, Basal Cell; Female; Fo	1995
Photodynamic therapy for psoriasis? The Australasian journal of dermatology, 1996, Volume: 37, Issue:2 Topics: Aminolevulinic Acid; Humans; Neoplasms; Photochemotherapy; Psoriasis; Radiation-Sensitizing Agents;	1996
Photodynamic therapy with systemic administration of photosensitizers in dermatology. Journal of photochemistry and photobiology. B, Biology, 1996, Volume: 36, Issue:2 Topics: Aminolevulinic Acid; Bowen's Disease; Breast Neoplasms; Dermatology; Dihematoporphyrin Ether; Female	1996
5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer, 1997, Jun-15, Volume: 79, Issue:12 Topics: Aminolevulinic Acid; Forecasting; Heme; Humans; Neoplasms; Photochemotherapy; Protoporphyrins; Resea	1997
Photodynamic therapy of superficial basal cell carcinoma by instillation of aminolevulinic acid and irradiation with visible light. Archives of dermatology, 1997, Volume: 133, Issue:12 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Injections, Intralesional; Male; Middle Aged; Ph	1997
[Medical treatment of epitheliomas]. Revista clinica espanola, 1997, Volume: 197, Issue:12 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Bowen's Disease; Carcinoma; Car	1997
Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): current clinical and development status. Journal of clinical laser medicine & surgery, 1996, Volume: 14, Issue:2 Topics: Aminolevulinic Acid; Animals; Endometrium; Female; Gastrointestinal Neoplasms; Humans; Laser Therapy	1996
Photodynamic therapy in dermatology. Archives of dermatology, 1998, Volume: 134, Issue:2 Topics: Administration, Cutaneous; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Cel	1998
[Use of 5-aminolevulinic acid in photochemotherapy and fluorescence diagnostics]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 1998, Mar-20, Volume: 118, Issue:8 Topics: Aminolevulinic Acid; Fluorescence; Heme; Humans; Photochemotherapy; Protoporphyrins; Skin Diseases;	1998
[Topical photodynamic therapy in dermatology]. Therapeutische Umschau. Revue therapeutique, 1998, Volume: 55, Issue:8 Topics: Aminolevulinic Acid; Humans; Photochemotherapy; Precancerous Conditions; Skin Neoplasms; Treatment O	1998
Optimum porphyrin accumulation in epithelial skin tumours and psoriatic lesions after topical application of delta-aminolaevulinic acid. British journal of cancer, 1999, Volume: 79, Issue:9-10 Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Human	1999
Basal cell carcinoma--new aspects of diagnosis and treatment. Acta dermato-venereologica. Supplementum, 2000, Volume: 209 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Interferons; Laser-Doppler Flowmetry; Microdialy	2000
Role of lasers and photodynamic therapy in the treatment of cutaneous malignancy. American journal of clinical dermatology, 2001, Volume: 2, Issue:4 Topics: Aged; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinica	2001
Topical 5-aminolevulinic acid and photodynamic therapy in dermatology: a minireview. Journal of chemotherapy (Florence, Italy), 2001, Volume: 13, Issue:5 Topics: Administration, Topical; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Clinical Trial	2001
Aminolevulinic acid: pharmacological profile and clinical indication. Expert opinion on investigational drugs, 2001, Volume: 10, Issue:6 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Clinical Trials as Topic; Drug Evaluation; Humans; Photo	2001
Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. The British journal of dermatology, 2002, Volume: 146, Issue:2 Topics: Acne Vulgaris; Aminolevulinic Acid; Humans; Lymphoma, T-Cell; Photochemotherapy; Photosensitizing Ag	2002
Guidelines for topical photodynamic therapy: report of a workshop of the British Photodermatology Group. The British journal of dermatology, 2002, Volume: 146, Issue:4 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Health Care Costs; Humans; Keratosis; L	2002
The emerging role of 5-ALA-PDT in dermatology: is PDT superior to standard treatments? The Journal of dermatological treatment, 2002, Volume: 13 Suppl 1 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis; Photochemotherapy; P	2002

Article	Year
A randomized assessor-blinded comparison of low-irradiance and conventional-irradiance photodynamic therapy for superficial basal cell carcinoma and Bowen disease. The British journal of dermatology, 2022, Volume: 186, Issue:3 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensiti	2022
Long-Term Efficacy of Photodynamic Therapy with Fractionated 5-Aminolevulinic Acid 20% versus Conventional Two-Stage Topical Methyl Aminolevulinate for Superficial Basal-Cell Carcinoma. Dermatology (Basel, Switzerland), 2022, Volume: 238, Issue:6 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Sing	2022
Laser-assisted MAL-PDT associated with acoustic pressure wave ultrasound with short incubation time for field cancerization treatment: A left-right comparison. Photodiagnosis and photodynamic therapy, 2019, Volume: 28 Topics: Adult; Aged; Aminolevulinic Acid; Combined Modality Therapy; Elasticity Imaging Techniques; Female;	2019
Hexyl aminolevulinate, 5-aminolevulinic acid nanoemulsion and methyl aminolevulinate in photodynamic therapy of non-aggressive basal cell carcinomas: A non-sponsored, randomized, prospective and double-blinded trial. Journal of the European Academy of Dermatology and Venereology : JEADV, 2020, Volume: 34, Issue:12 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Photochemotherapy; Photosensitizing Agents; Pros	2020
A Randomized Trial of Broad Area ALA-PDT for Field Cancerization Mitigation in High-Risk Patients. Journal of drugs in dermatology : JDD, 2020, May-01, Volume: 19, Issue:5 Topics: Aged; Aminolevulinic Acid; Combined Modality Therapy; Cryotherapy; Disease Progression; Female; Huma	2020
CO2 laser ablative fractional resurfacing photodynamic therapy for actinic keratosis and nonmelanoma skin cancer: a randomized split-side study. Cutis, 2020, Volume: 105, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Combined Modality Therapy; Dose Fractionation,	2020
Treatment of superficial basal cell carcinoma with 7.8% 5-aminolaevulinic acid nanoemulsion-based gel (BF-200 ALA) and photodynamic therapy: Results in clinical practice in a tertiary hospital. Dermatologic therapy, 2021, Volume: 34, Issue:1 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Middle Aged; Photochemotherapy; Ph	2021
A Clinical Trial Using Attrition Combined with 5-Aminolevulinic Acids Based Photodynamic Therapy in Treating Squamous Cell Carcinoma. Medical science monitor : international medical journal of experimental and clinical research, 2017, Mar-18, Volume: 23 Topics: Aged; Aminolevulinic Acid; Apoptosis; Carcinoma, Squamous Cell; Combined Modality Therapy; Female; H	2017
Patient preferences for the attributes of a noninvasive treatment for superficial basal cell carcinoma: a discrete choice experiment. The British journal of dermatology, 2018, Volume: 178, Issue:1 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Choice Behavior; Dermatologic Agents; Drug Therapy, Comb	2018
Treatment of superficial basal cell carcinoma by topical photodynamic therapy with fractionated 5-aminolaevulinic acid 20% vs. two-stage topical methyl aminolaevulinate: results of a randomized controlled trial. The British journal of dermatology, 2018, Volume: 178, Issue:5 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel	2018
Combination vismodegib and photodynamic therapy for multiple basal cell carcinomas. Photodiagnosis and photodynamic therapy, 2018, Volume: 21 Topics: Aged; Aminolevulinic Acid; Anilides; Antineoplastic Agents; Carcinoma, Basal Cell; Combined Modality	2018
A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminolaevulinate cream in the treatment of nonaggressive basal cell carcinoma with photodynamic therapy. The British journal of dermatology, 2018, Volume: 179, Issue:2 Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; M	2018
PHOTODYNAMIC TREATMENT WITH NANOEMULSIFIED 5-AMINOLEVULINIC ACID AND NARROW BAND RED LIGHT FOR FIELD CANCERIZATION DUE TO OCCUPATIONAL EXPOSURE TO ULTRAVIOLET LIGHT IRRADIATION. Georgian medical news, 2018, Issue:274 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Sq	2018
Blue light versus red light for photodynamic therapy of basal cell carcinoma in patients with Gorlin syndrome: A bilaterally controlled comparison study. Photodiagnosis and photodynamic therapy, 2018, Volume: 22 Topics: Adult; Aminolevulinic Acid; Basal Cell Nevus Syndrome; Carcinoma, Basal Cell; Female; Humans; Light;	2018
Ablative fractional laser-assisted photodynamic therapy provides superior long-term efficacy compared with standard methyl aminolevulinate photodynamic therapy for lower extremity Bowen disease. Journal of the American Academy of Dermatology, 2018, Volume: 79, Issue:5 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy, Needle; Bowen's Disease; Combined Modality The	2018
Effectiveness and safety of 0·5% colchicine cream vs. photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratosis and skin field cancerization of the forearms: a randomized controlled trial. The British journal of dermatology, 2018, Volume: 179, Issue:5 Topics: Aged; Aminolevulinic Acid; Atrophy; Biopsy; Carcinoma, Squamous Cell; Colchicine; Disease Progressio	2018
Short incubation fractional CO Journal of the European Academy of Dermatology and Venereology : JEADV, 2019, Volume: 33, Issue:1 Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carc	2019
Enhancement of Photodynamic Therapy for Bowen's Disease Using Plum-Blossom Needling to Augment Drug Delivery. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2018, Volume: 44, Issue:12 Topics: Aged; Aminolevulinic Acid; Bowen's Disease; Drug Delivery Systems; Female; Fluorescence; Humans; Mal	2018
Long-term efficacy of photodynamic therapy with methyl aminolevulinate in treating Bowen's disease in clinical practice: A retrospective cohort study (2006-2017). Photodermatology, photoimmunology & photomedicine, 2019, Volume: 35, Issue:4 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Disease-Free Survival; Female; Humans	2019
Methyl aminolevulinate-based photodynamic therapy of Bowen´s disease: Observational study of 21 lesions. Photodiagnosis and photodynamic therapy, 2019, Volume: 26 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Female; Humans; Male; Middle Aged; Ph	2019
Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up. Journal of the American Academy of Dermatology, 2013, Volume: 69, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therap	2013
A pilot split-face study comparing conventional methyl aminolevulinate-photodynamic therapy (PDT) with microneedling-assisted PDT on actinically damaged skin. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2013, Volume: 39, Issue:8 Topics: Aged; Aminolevulinic Acid; Female; Humans; Keratosis, Actinic; Lasers, Gas; Male; Middle Aged; Pain	2013
Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. The Lancet. Oncology, 2013, Volume: 14, Issue:7 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Antim	2013
A prospective pilot study to evaluate combined topical photodynamic therapy and surgery for extramammary paget's disease. Lasers in surgery and medicine, 2013, Volume: 45, Issue:5 Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Cohort Studies; Combined Moda	2013
A randomized trial comparing methyl aminolaevulinate photodynamic therapy with and without Er:YAG ablative fractional laser treatment in Asian patients with lower extremity Bowen disease: results from a 12-month follow-up. The British journal of dermatology, 2014, Volume: 170, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Asian People; Bowen's Disease; Female; Follow-U	2014
Optical coherence tomography imaging of non-melanoma skin cancer undergoing photodynamic therapy reveals subclinical residual lesions. Photodiagnosis and photodynamic therapy, 2014, Volume: 11, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Keratosi	2014
Prolonged adverse events following photodynamic therapy: regulatory implications. Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:1 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Australia; Biopsy; Early Termination of Clinical Trial	2014
Experience and BCC subtypes as determinants of MAL-PDT response: preliminary results of a national Brazilian project. Photodiagnosis and photodynamic therapy, 2014, Volume: 11, Issue:1 Topics: Aminolevulinic Acid; Brazil; Carcinoma, Basal Cell; Female; Humans; Male; Photochemotherapy; Photose	2014
Efficacy of topical ALA-PDT combined with excision in the treatment of skin malignant tumor. Photodiagnosis and photodynamic therapy, 2014, Volume: 11, Issue:2 Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Chemotherapy, Adjuvant; Derma	2014
Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma. The British journal of dermatology, 2014, Volume: 171, Issue:6 Topics: Administration, Cutaneous; Aminolevulinic Acid; Aminoquinolines; Antineoplastic Combined Chemotherap	2014
Novel photodynamic therapy does not prevent new skin cancers--randomized controlled trial. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2014, Volume: 40, Issue:4 Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Facial Neoplasms; Female	2014
Fractional laser-mediated photodynamic therapy of high-risk basal cell carcinomas--a randomized clinical trial. The British journal of dermatology, 2015, Volume: 172, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therap	2015
Effect of methylene blue-mediated photodynamic therapy for treatment of basal cell carcinoma. Lasers in medical science, 2015, Volume: 30, Issue:1 Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Methylene Blue; Middl	2015
Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial. The British journal of dermatology, 2015, Volume: 172, Issue:3 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Aminoquinolines; Ant	2015
Does fluorescence diagnosis have a role in follow up of response to therapy in mycosis fungoides? Photodiagnosis and photodynamic therapy, 2014, Volume: 11, Issue:4 Topics: Adolescent; Adult; Aged; Aminolevulinic Acid; Contrast Media; Dermoscopy; Female; Follow-Up Studies;	2014
Efficacy and safety of topical ALA-PDT in the treatment of EMPD. Photodiagnosis and photodynamic therapy, 2015, Volume: 12, Issue:1 Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Combined Modality Therapy;	2015
Photodynamic therapy in combination with CO2 laser for the treatment of Bowen's disease. Lasers in medical science, 2015, Volume: 30, Issue:5 Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Bowen's Disease; Carcinoma in Situ; Doubl	2015
Development of a handheld fluorescence imaging device to investigate the characteristics of protoporphyrin IX fluorescence in healthy and diseased skin. Photodiagnosis and photodynamic therapy, 2015, Volume: 12, Issue:4 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Optical Imaging; Photosensit	2015
Er:YAG ablative fractional laser-primed photodynamic therapy with methyl aminolevulinate as an alternative treatment option for patients with thin nodular basal cell carcinoma: 12-month follow-up results of a randomized, prospective, comparative trial. Journal of the European Academy of Dermatology and Venereology : JEADV, 2016, Volume: 30, Issue:5 Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Humans; Lasers, Solid-S	2016
Is the thin layer of methyl aminolevulinate used during photodynamic therapy sufficient? Photodermatology, photoimmunology & photomedicine, 2016, Volume: 32, Issue:2 Topics: Adenocarcinoma; Aged; Aminolevulinic Acid; Female; Humans; Keratosis, Actinic; Male; Photochemothera	2016
Preliminary results of comparative study for subsequent photodynamic therapy versus secondary excision after primary excision for treating basal cell carcinoma. Photodiagnosis and photodynamic therapy, 2017, Volume: 17 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Disease-Free Survival; F	2017
Glycolysis inhibition improves photodynamic therapy response rates for equine sarcoids. Veterinary and comparative oncology, 2017, Volume: 15, Issue:4 Topics: Aminolevulinic Acid; Animals; Cell Line, Tumor; Glycolysis; Horse Diseases; Horses; Photochemotherap	2017
Effect of Methyl Aminolevulinate Photodynamic Therapy With and Without Ablative Fractional Laser Treatment in Patients With Microinvasive Squamous Cell Carcinoma: A Randomized Clinical Trial. JAMA dermatology, 2017, 03-01, Volume: 153, Issue:3 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Squamous Cell; Female; Humans; Lasers, Soli	2017
Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma. The British journal of dermatology, 2008, Volume: 159, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Dose-Response Relationsh	2008
A clinical study comparing methyl aminolevulinate photodynamic therapy and surgery in small superficial basal cell carcinoma (8-20 mm), with a 12-month follow-up. Journal of the European Academy of Dermatology and Venereology : JEADV, 2008, Volume: 22, Issue:11 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell;	2008
Fractionated 5-aminolaevulinic acid-photodynamic therapy vs. surgical excision in the treatment of nodular basal cell carcinoma: results of a randomized controlled trial. The British journal of dermatology, 2008, Volume: 159, Issue:4 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Middle Aged; Net	2008
Fractionated illumination improves the outcome in the treatment of precancerous lesions with photodynamic therapy. Collegium antropologicum, 2008, Volume: 32 Suppl 2 Topics: Aminolevulinic Acid; Bowen's Disease; Humans; Keratosis, Actinic; Neoplasm, Residual; Photochemother	2008
A time course investigation of the fluorescence induced by topical application of 5-aminolevulinic acid and methyl aminolevulinate on normal human skin. Photodermatology, photoimmunology & photomedicine, 2009, Volume: 25, Issue:4 Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Female; Fluorescence; Humans; Male; Middl	2009
Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. The British journal of dermatology, 2010, Volume: 162, Issue:1 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Facia	2010
Reduction in the incidence of squamous cell carcinoma in solid organ transplant recipients treated with cyclic photodynamic therapy. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2010, Volume: 36, Issue:5 Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Incid	2010
Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes. Journal of drugs in dermatology : JDD, 2009, Volume: 8, Issue:11 Topics: Aged; Aminolevulinic Acid; Belgium; Carcinoma, Basal Cell; Female; Humans; Male; Middle Aged; Photoc	2009
Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. International journal of dermatology, 2009, Volume: 48, Issue:11 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studie	2009
[Plaque-phase mycosis fungoides treated with photodynamic therapy: results from 12 patients]. Actas dermo-sifiliograficas, 2010, Volume: 101, Issue:9 Topics: Adrenal Cortex Hormones; Adult; Aminolevulinic Acid; Combined Modality Therapy; Female; Fluorescence	2010
Protoporphyrin IX photobleaching during the light irradiation phase of standard dermatological methyl-aminolevulinate photodynamic therapy. Photodiagnosis and photodynamic therapy, 2010, Volume: 7, Issue:4 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Female; Humans; Male; Photobleaching; Photochemotherap	2010
Photodynamic therapy-induced immunosuppression in humans is prevented by reducing the rate of light delivery. The Journal of investigative dermatology, 2011, Volume: 131, Issue:4 Topics: Adult; Aged; Aminolevulinic Acid; Dose-Response Relationship, Radiation; Drug Therapy, Combination;	2011
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites. The British journal of dermatology, 2011, Volume: 164, Issue:6 Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo	2011
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites. The British journal of dermatology, 2011, Volume: 164, Issue:6 Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo	2011
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites. The British journal of dermatology, 2011, Volume: 164, Issue:6 Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo	2011
Comparison of protoporphyrin IX accumulation and destruction during methylaminolevulinate photodynamic therapy of skin tumours located at acral and nonacral sites. The British journal of dermatology, 2011, Volume: 164, Issue:6 Topics: Adult; Aged; Aminolevulinic Acid; Analysis of Variance; Extremities; Facial Dermatoses; Female; Fluo	2011
Long-term follow-up of metil aminolevulinate (MAL)-PDT in difficult-to-treat cutaneous Bowen's disease. International journal of dermatology, 2011, Volume: 50, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Female; Follow-Up Studies; Hum	2011
PpIX fluorescence combined with auto-fluorescence is more accurate than PpIX fluorescence alone in fluorescence detection of non-melanoma skin cancer: an intra-patient direct comparison study. Lasers in surgery and medicine, 2012, Volume: 44, Issue:4 Topics: Aminolevulinic Acid; Biomarkers, Tumor; Bowen's Disease; Carcinoma; Carcinoma, Basal Cell; False Neg	2012
Topical photodynamic therapy significantly reduces epidermal Langerhans cells during clinical treatment of basal cell carcinoma. The British journal of dermatology, 2012, Volume: 166, Issue:5 Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Langerh	2012
The application of Levulan-based photodynamic therapy with imiquimod in the treatment of recurrent basal cell carcinoma. Medical science monitor : international medical journal of experimental and clinical research, 2012, Volume: 18, Issue:2 Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male; Middle Aged; Neoplasm Recurr	2012
Photodynamic therapy for multiple eruptive keratoacanthomas associated with vemurafenib treatment for metastatic melanoma. Archives of dermatology, 2012, Volume: 148, Issue:3 Topics: Aged; Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease Progression; Dru	2012
Effect of an oxygen pressure injection (OPI) device on the oxygen saturation of patients during dermatological methyl aminolevulinate photodynamic therapy. Lasers in medical science, 2013, Volume: 28, Issue:3 Topics: Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Humans; Keratosis, Actinic; Oxygen; Pho	2013
Light fractionation significantly improves the response of superficial basal cell carcinoma to aminolaevulinic acid photodynamic therapy: five-year follow-up of a randomized, prospective trial. Acta dermato-venereologica, 2012, Volume: 92, Issue:6 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel	2012
The time-dependent accumulation of protoporphyrin IX fluorescence in nodular basal cell carcinoma following application of methyl aminolevulinate with an oxygen pressure injection device. Journal of photochemistry and photobiology. B, Biology, 2012, Dec-05, Volume: 117 Topics: Aminolevulinic Acid; Biological Transport; Carcinoma, Basal Cell; Injections; Oxygen; Photosensitizi	2012
Fluorescence contrast and threshold limit: implications for photodynamic diagnosis of basal cell carcinoma. Journal of photochemistry and photobiology. B, Biology, 2003, Volume: 69, Issue:2 Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Facial Neoplasms; Humans; Image	2003
Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen's disease. The British journal of dermatology, 2003, Volume: 148, Issue:3 Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Antimetabolites, Antineoplast	2003
The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy. The British journal of dermatology, 2003, Volume: 149, Issue:1 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Car	2003
Topical methyl aminolaevulinate photodynamic therapy in patients with basal cell carcinoma prone to complications and poor cosmetic outcome with conventional treatment. The British journal of dermatology, 2003, Volume: 149, Issue:6 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell;	2003
Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Archives of dermatology, 2004, Volume: 140, Issue:1 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell;	2004
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. The British journal of dermatology, 2004, Volume: 151, Issue:1 Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Heart Transplant	2004
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. The British journal of dermatology, 2004, Volume: 151, Issue:1 Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Heart Transplant	2004
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. The British journal of dermatology, 2004, Volume: 151, Issue:1 Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Heart Transplant	2004
A randomized controlled clinical trial of topical photodynamic therapy with methyl aminolaevulinate in the treatment of actinic keratoses in transplant recipients. The British journal of dermatology, 2004, Volume: 151, Issue:1 Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Follow-Up Studies; Heart Transplant	2004
New proposal for the treatment of nodular basal cell carcinoma with intralesional 5-aminolevulinic acid. Journal of chemotherapy (Florence, Italy), 2004, Volume: 16, Issue:5 Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Injections, Intralesional;	2004
Clinical system for interstitial photodynamic therapy with combined on-line dosimetry measurements. Applied optics, 2005, Jul-01, Volume: 44, Issue:19 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Computer Systems; Equipment Design; Equipment Failure An	2005
[Photodynamic therapy with methylaminooxopentanoate (Metvix) and a broad band light source (PhotoDyn 501): practical experiences in problem-patients with actinic keratoses and basal cell carcinomas]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2004, Volume: 2, Issue:12 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Keratosis; Ligh	2004
Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. The Journal of investigative dermatology, 2006, Volume: 126, Issue:2 Topics: Administration, Topical; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Double-Blind Method; Fema	2006
Photodynamic therapy does not prevent cutaneous squamous-cell carcinoma in organ-transplant recipients: results of a randomized-controlled trial. The Journal of investigative dermatology, 2006, Volume: 126, Issue:3 Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Squamous Cell; Female; Humans; Keratosis; Male; Middle	2006
Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2006, Volume: 25, Issue:1-2 Topics: Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Fluorescence; Humans; Lasers; Male;	2006
Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta dermato-venereologica, 2006, Volume: 86, Issue:1 Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Im	2006
Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. Archives of dermatology, 2006, Volume: 142, Issue:6 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Antimetabolites, Ant	2006
Fractionated illumination significantly improves the response of superficial basal cell carcinoma to aminolevulinic acid photodynamic therapy. The Journal of investigative dermatology, 2006, Volume: 126, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Darkness; Humans; Light;	2006
Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatology, photoimmunology & photomedicine, 2006, Volume: 22, Issue:5 Topics: Administration, Cutaneous; Adult; Aged; Aminolevulinic Acid; Female; Humans; Lymphoma, T-Cell, Cutan	2006
Morphine gel 0.3% does not relieve pain during topical photodynamic therapy: a randomized, double-blind, placebo-controlled study. Acta dermato-venereologica, 2006, Volume: 86, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Double-Blind Method; Gel	2006
Topical 5-aminolevulinic acid mediated photodynamic therapy of superficial basal cell carcinoma using two light fractions with a two-hour interval: long-term follow-up. Acta dermato-venereologica, 2006, Volume: 86, Issue:5 Topics: Administration, Topical; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Fluorescence; Humans; M	2006
Economic evaluation of methyl aminolaevulinate-based photodynamic therapy in the management of actinic keratosis and basal cell carcinoma. The British journal of dermatology, 2006, Volume: 155, Issue:4 Topics: Aminolevulinic Acid; Belgium; Carcinoma, Basal Cell; Cost-Benefit Analysis; Cryosurgery; Decision Ma	2006
Treatment of post-transplant premalignant skin disease: a randomized intrapatient comparative study of 5-fluorouracil cream and topical photodynamic therapy. The British journal of dermatology, 2007, Volume: 156, Issue:2 Topics: Administration, Topical; Aged; Aminolevulinic Acid; Antimetabolites, Antineoplastic; Bowen's Disease	2007
Response of Bowen disease to ALA-PDT using a single and a 2-fold illumination scheme. Archives of dermatology, 2007, Volume: 143, Issue:2 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Female; Humans; Male; Middle Aged; Ph	2007
Photodynamic therapy with methyl aminolevulinate for atypial carcinoma in situ of the penis. Scandinavian journal of urology and nephrology, 2007, Volume: 41, Issue:6 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Bowen's Disease; Humans; Male; Middle Aged; Pe	2007
Five-year follow-up of a randomized, prospective trial of topical methyl aminolevulinate photodynamic therapy vs surgery for nodular basal cell carcinoma. Archives of dermatology, 2007, Volume: 143, Issue:9 Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female	2007
A clinical investigation to determine the effect of pressure injection on the penetration of topical methyl aminolevulinate into nodular basal cell carcinoma of the skin. Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer, 2007, Volume: 26, Issue:4 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Drug Delivery Systems; Humans; Injections, Intralesional	2007
Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma. Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:8 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cell Line, Tumor; Humans; In Vi	2008
Combination of Er:YAG laser and photodynamic therapy in the treatment of nodular basal cell carcinoma. Lasers in surgery and medicine, 2008, Volume: 40, Issue:2 Topics: Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Combined Modality Therapy; Follow-Up Studies; Head	2008
Does surface preparation alter ALA uptake in superficial non-melanoma skin cancer in vivo? Photodermatology, photoimmunology & photomedicine, 2008, Volume: 24, Issue:2 Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cure	2008
Repetitive photodynamic therapy with topical delta-aminolaevulinic acid as an appropriate approach to the routine treatment of superficial non-melanoma skin tumours. Journal of photochemistry and photobiology. B, Biology, 1995, Volume: 29, Issue:1 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell;	1995
Superficial photodynamic therapy with topical 5-aminolaevulinic acid for superficial primary and secondary skin cancer. British journal of cancer, 1994, Volume: 69, Issue:3 Topics: Adenocarcinoma; Administration, Topical; Aminolevulinic Acid; Bowen's Disease; Breast Neoplasms; Car	1994
Lack of selectivity of protoporphyrin IX fluorescence for basal cell carcinoma after topical application of 5-aminolevulinic acid: implications for photodynamic treatment. Archives of dermatological research, 1995, Volume: 287, Issue:7 Topics: Administration, Cutaneous; Adult; Aminolevulinic Acid; Carcinoma, Basal Cell; Female; Humans; Male;	1995
Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. Archives of dermatological research, 1996, Volume: 288, Issue:10 Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cel	1996
Superficial blood flow following photodynamic therapy of malignant non-melanoma skin tumours measured by laser Doppler perfusion imaging. The British journal of dermatology, 1997, Volume: 136, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Female;	1997
Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid. Photochemistry and photobiology, 1998, Volume: 67, Issue:2 Topics: Administration, Oral; Aminolevulinic Acid; Carcinoma, Basal Cell; Drug Interactions; Fluorescence; H	1998
Long-term follow-up and histological changes of superficial nonmelanoma skin cancers treated with topical delta-aminolevulinic acid photodynamic therapy. Archives of dermatology, 1998, Volume: 134, Issue:7 Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Antineoplastic Agents; Carcin	1998
Photodynamic therapy of superficial basal cell carcinomas using topical 5-aminolevulinic acid in a nanocolloid lotion. Dermatology (Basel, Switzerland), 1998, Volume: 197, Issue:3 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma, Bas	1998
In vivo detection of basal cell carcinoma using imaging spectroscopy. Acta dermato-venereologica, 1999, Volume: 79, Issue:1 Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Aminolevulinic Acid; Biopsy; Carcinoma, Basal Ce	1999
Kinetic fluorescence studies of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation in basal cell carcinomas. Journal of photochemistry and photobiology. B, Biology, 1999, Volume: 49, Issue:2-3 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell;	1999
Preliminary evaluation of two fluorescence imaging methods for the detection and the delineation of basal cell carcinomas of the skin. Lasers in surgery and medicine, 2000, Volume: 26, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Humans; Male; Photosensi	2000
A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. Journal of controlled release : official journal of the Controlled Release Society, 2000, Apr-03, Volume: 65, Issue:3 Topics: Aminolevulinic Acid; Animals; Dimethyl Sulfoxide; Humans; Mice; Mice, Hairless; Microscopy, Confocal	2000
Photodynamic therapy of superficial basal cell carcinoma with 5-aminolevulinic acid with dimethylsulfoxide and ethylendiaminetetraacetic acid: a comparison of two light sources. Photochemistry and photobiology, 2000, Volume: 71, Issue:6 Topics: Aminolevulinic Acid; Carcinoma, Basal Cell; Dimethyl Sulfoxide; Edetic Acid; Female; Humans; Light;	2000
[Topical photodynamic therapy in basal and squamous cell carcinoma and penile Bowen's disease with 20% aminolevulinic acid, and exposure to red light and infrared light]. Harefuah, 1998, Apr-15, Volume: 134, Issue:8 Topics: Administration, Topical; Adult; Aged; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; C	1998
Topical delta-aminolevulinic acid-based photodynamic therapy for Japanese actinic keratoses. The Journal of dermatology, 2000, Volume: 27, Issue:8 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Arm; Asian People; Carcinoma, Squamous Cell; Facial De	2000
Comparison of red and green light in the treatment of Bowen's disease by photodynamic therapy. The British journal of dermatology, 2000, Volume: 143, Issue:4 Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Follow-Up Studies; Humans; Middle Age	2000
Photodynamic therapy of residual or recurrent basal cell carcinoma after radiotherapy using topical 5-aminolevulinic acid or methylester aminolevulinic acid. Acta oncologica (Stockholm, Sweden), 2000, Volume: 39, Issue:5 Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Female	2000
Routine double treatments of superficial basal cell carcinomas using aminolaevulinic acid-based photodynamic therapy. The British journal of dermatology, 2000, Volume: 143, Issue:6 Topics: Administration, Cutaneous; Aged; Aminolevulinic Acid; Carcinoma, Basal Cell; Follow-Up Studies; Huma	2000
Photodynamic therapy for large or multiple patches of Bowen disease and basal cell carcinoma. Archives of dermatology, 2001, Volume: 137, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carcinoma, Basal Cell; Female;	2001
Selective distribution of porphyrins in skin thick basal cell carcinoma after topical application of methyl 5-aminolevulinate. Journal of photochemistry and photobiology. B, Biology, 2001, Sep-15, Volume: 62, Issue:3 Topics: Administration, Topical; Aged; Aged, 80 and over; Aminolevulinic Acid; Analysis of Variance; Carcino	2001
Photodynamic therapy with violet light and topical 6-aminolaevulinic acid in the treatment of actinic keratosis, Bowen's disease and basal cell carcinoma. Journal of the European Academy of Dermatology and Venereology : JEADV, 2001, Volume: 15, Issue:6 Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Bowen's Disease; Carci	2001
Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. Journal of photochemistry and photobiology. B, Biology, 1990, Volume: 6, Issue:1-2 Topics: Aminolevulinic Acid; Animals; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratosis; Ph	1990

Authors	Studies
McEwan, C	1
Nesbitt, H	1
Nicholas, D	1
Kavanagh, ON	1
McKenna, K	3
Loan, P	1
Jack, IG	1
McHale, AP	1
Callan, JF	1
Ibbotson, SH	10
Ferguson, J	8
Moseley, H	11
Samuel, IDW	2
Lesar, A	4
Dawe, RS	2
Liao, C	4
Shi, L	9
Wang, D	3
Wang, X	28
Lv, T	5
Huang, J	1
Wu, M	2
Wang, H	5
Zeng, Q	6
George, A	1
Shrivastav, PS	1
Salvio, AG	6
Veneziano, DB	1
Moriyama, LT	3
Inada, NM	2
Grecco, C	1
Kurachi, C	6
Bagnato, VS	8
Condorelli, AG	1
Motolese, A	2
Borgia, F	1
Bartolomeo, LD	1
Bianchi, L	1
Rossi, PG	1
Ottone, M	1

aminolevulinic acid and Skin Neoplasms